bcda20180630

Large accelerated filer

Accelerated filer

Non-accelerated filer

☐ (Do not check if a smaller reporting company)

Smaller reporting company

Emerging growth company

0001437749-18-015094.txt : 20180809 0001437749-18-015094.hdr.sgml : 20180809 20180809153150 ACCESSION NUMBER: 0001437749-18-015094 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 53 CONFORMED PERIOD OF REPORT: 20180630 FILED AS OF DATE: 20180809 DATE AS OF CHANGE: 20180809 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BioCardia, Inc. CENTRAL INDEX KEY: 0000925741 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 232753988 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-21419 FILM NUMBER: 181004792 BUSINESS ADDRESS: STREET 1: 125 SHOREWAY ROAD STREET 2: SUITE B CITY: SAN CARLOS STATE: CA ZIP: 94070 BUSINESS PHONE: 650-226-0123 MAIL ADDRESS: STREET 1: 125 SHOREWAY ROAD STREET 2: SUITE B CITY: SAN CARLOS STATE: CA ZIP: 94070 FORMER COMPANY: FORMER CONFORMED NAME: Tiger X Medical, Inc. DATE OF NAME CHANGE: 20110616 FORMER COMPANY: FORMER CONFORMED NAME: Cardo Medical, Inc. DATE OF NAME CHANGE: 20081027 FORMER COMPANY: FORMER CONFORMED NAME: CLICKNSETTLE COM INC DATE OF NAME CHANGE: 20000823 10-Q 1 bcda20180630_10q.htm FORM 10-Q bcda20180630_10q.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2018

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission file number: 0-21419

BioCardia, Inc.

(Exact name of registrant as specified in its charter)

Delaware

23-2753988

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer

Identification Number)

125 Shoreway Road, Suite B

San Carlos, California 94070

(Address of principal executive offices including zip code)

(650) 226-0120

(Registrant’s telephone number, including area code)

N/A

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

There were 38,277,908 shares of the registrant’s Common Stock issued and outstanding as of August 9, 2018.

Part I. FINANCIAL INFORMATION		3

Item 1.	Unaudited Condensed Consolidated Financial Statements	3
	Condensed Consolidated Balance Sheets as of June 30, 2018 and December 31, 2017	3
	Condensed Consolidated Statements of Operations for the three and six months ended June 30, 2018 and 2017	4
	Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2018 and 2017	5
	Notes to Unaudited Condensed Consolidated Financial Statements	6
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	13
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	20
Item 4.	Controls and Procedures	20

Part II. OTHER INFORMATION		21

Item 1.	Legal Proceedings	21
Item 1A.	Risk Factors	21
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	21
Item 3.	Defaults Upon Senior Securities	21
Item 4.	Mine Safety Disclosures	21
Item 5.	Other Information	21
Item 6.	Exhibits	21

SIGNATURES		22
EXHIBIT INDEX		23

FORWARD-LOOKING INFORMATION

This Quarterly Report on Form 10-Q, or report, contains forward-looking statements within the meaning of the U.S. federal securities laws that involve risks and uncertainties. Certain statements contained in this report are not purely historical including, without limitation, statements regarding our expectations, beliefs, intentions, anticipations, commitments or strategies regarding the future that are forward-looking. These statements include those discussed in Item 2, Management’s Discussion and Analysis of Financial Condition and Results of Operations, including “Critical Accounting Policies and Estimates,” “Results of Operations,” “Liquidity and Capital Resources,” and “Future Funding Requirements,” and elsewhere in this report.

In this report, the words “may,” “could,” “would,” “might,” “will,” “should,” “plan,” “ forecast,” “anticipate,” “believe,” “expect,” “intend,” “estimate,” “predict,” “potential,” “continue,” “future,” “moving toward” or the negative of these terms or other similar expressions also identify forward-looking statements. Our actual results could differ materially from those forward-looking statements contained in this report as a result of a number of risk factors including, but not limited to, those listed in our Annual Report on Form 10-K and elsewhere in this report. You should carefully consider these risks, in addition to the other information in this report and in our other filings with the SEC. All forward-looking statements and reasons why results may differ included in this report are made as of the date of this report, and we undertake no obligation to update any such forward-looking statement or reason why such results might differ after the date of this Quarterly Report on Form 10-Q, except as required by law.

PART I. FINANCIAL INFORMATION

ITEM 1. UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

BIOCARDIA, INC.

Condensed Consolidated Balance Sheets

(In thousands, except share and per share amounts)

	June 30, 2018			December 31, 2017
	(unaudited)
Assets

Current assets:
Cash and cash equivalents	$	6,834		$	12,689
Accounts receivable, net of allowance for doubtful accounts of $3 and $6 at June 30, 2018 and December 31, 2017, respectively		191			95
Inventory		136			191
Prepaid expenses		282			340
Total current assets		7,443			13,315
Property and equipment, net		164			169
Other assets		54			54
Total assets	$	7,661		$	13,538
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable	$	505		$	902
Accrued expenses and other current liabilities		1,314			1,263
Deferred revenue		—			167
Total current liabilities		1,819			2,332
Deferred rent		84			81
Total liabilities		1,903			2,413
Stockholders’ equity:
Preferred stock, $0.001 par value, 25,000,000 shares authorized; no shares issued and outstanding as of June 30, 2018 and December 31, 2017		—			—
Common stock, $0.001 par value, 100,000,000 shares authorized as of June 30, 2018 and December 31, 2017 respectively; 38,277,908 and 38,218,660 shares issued and outstanding as of June 30, 2018 and December 31, 2017, respectively		38			38
Additional paid-in capital		84,895			83,537
Accumulated deficit		(79,175	)		(72,450	)
Total stockholders’ equity		5,758			11,125
Total liabilities and stockholders’ equity	$	7,661		$	13,538

See accompanying notes to condensed consolidated financial statements.

BIOCARDIA, INC.

Condensed Consolidated Statements of Operations

(In thousands, except share and per share amounts)

(unaudited)

	Three months ended June 30,						Six months ended June 30,
	2018			2017			2018			2017
Revenue:
Net product revenue	$	89		$	101		$	171		$	210
Collaboration agreement revenue		150			11			267			39
Total revenue		239			112			438			249
Costs and expenses:
Cost of goods sold		135			203			292			378
Research and development		2,031			1,295			3,986			2,328
Selling, general and administrative		1,325			1,582			3,032			3,386
Total costs and expenses		3,491			3,080			7,310			6,092
Operating loss		(3,252	)		(2,968	)		(6,872	)		(5,843	)
Other income (expense):
Interest income		35			23			71			23
Other expense, net		—			—			—			(1	)
Total other income, net		35			23			71			22
Net loss	$	(3,217	)	$	(2,945	)	$	(6,801	)	$	(5,821	)

Net loss per share, basic and diluted	$	(0.08	)	$	(0.08	)	$	(0.18	)	$	(0.15	)

Weighted-average shares used in computing net loss per share, basic and diluted		38,247,288			38,140,232			38,242,728			38,139,063

See accompanying notes to condensed consolidated financial statements.

BIOCARDIA, INC.

Condensed Consolidated Statements of Cash Flows

(In thousands)

(unaudited)

	Six months ended June 30,
	2018			2017
Operating activities:
Net loss	$	(6,801	)	$	(5,821	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		44			36
Share-based compensation		1,353			1,298
Changes in operating assets and liabilities:
Accounts receivable		(96	)		(68	)
Inventory		55			(58	)
Prepaid expenses		58			74
Accounts payable		(390	)		60
Accrued liabilities		25			16
Deferred revenue		(65	)		82
Deferred rent		3			12
Net cash used in operating activities		(5,814	)		(4,369	)
Investing activities:
Purchase of property and equipment		(46	)		(100	)
Purchase of short-term investments		—			(1,796	)
Net used in in investing activities		(46	)		(1,896	)
Financing activities:
Proceeds from the exercise of common stock options		5			22
Net cash provided by financing activities		5			22
Net decrease in cash and cash equivalents		(5,855	)		(6,243	)
Cash and cash equivalents at beginning of period		12,689			21,352
Cash and cash equivalents at end of period	$	6,834		$	15,109

See accompanying notes to condensed consolidated financial statements.

(1)

Summary of Business and Basis of Presentation

Description of Business

BioCardia, Inc., (“we” or “the Company”), is a clinical-stage regenerative medicine company developing novel therapeutics for cardiovascular diseases with large unmet medical needs. Our lead therapeutic candidate is the CardiAMP Cell Therapy System, an investigational autologous bone marrow derived cell therapy being advanced for two large cardiac indications under FDA approved pivotal trials. Our second therapeutic candidate is the CardiALLO Cell Therapy System, an investigational allogenic culture expanded “off the shelf” mesenchymal cell therapy being advanced initially to treat patients who are not eligible for CardiAMP cell therapy due to the quality of their cells. To date, we have devoted substantially all our resources to research and development efforts relating to our therapeutic candidates and biotherapeutic delivery systems including conducting clinical trials, developing manufacturing and sales capabilities, in-licensing related intellectual property, providing general and administrative support for these operations and protecting our intellectual property.

We have three enabling device product lines which have one or more approvals in the USA and/or EU: (1) the CardiAMP cell processing system; (2) the Helix biotherapeutic delivery system, or Helix; and (3) the Morph vascular access product line, or Morph. We manage our operations as a single segment for the purposes of assessing performance and making operating decisions.

(2)

Significant Accounting Policies

(a)

Basis of Preparation

The accompanying condensed consolidated balance sheets, statements of operations and cash flows as of and for the three and six months ended June 30, 2018 and 2017 are unaudited. The condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America, or U.S. GAAP, and applicable rules and regulations of the Securities and Exchange Commission, or SEC, for interim financial information and on a basis consistent with the annual financial statements. In the opinion of management, they also reflect all adjustments which include only normal recurring adjustments, necessary to present fairly our financial position for the interim periods presented. The results for the three and six months ended June 30, 2018 are not necessarily indicative of the results to be expected for the year ending December 31, 2018 or for any other interim period or for any other future year.

These condensed consolidated financial statements should be read in conjunction with the audited financial statements and related notes included in our Annual Report on Form 10-K for the year ended December 31, 2017, filed with the SEC on March 16, 2018.

(b)

Liquidity

We have incurred net losses and negative cash flows from operations since our inception and had an accumulated deficit of $79.2 million as of June 30, 2018. Management expects operating losses and negative cash flows to continue through the next several years. Based on management’s current plans, management believes cash and cash equivalents of $6.8 million as of June 30, 2018 are sufficient to fund us into December 2018. These factors raise substantial doubt about our ability to continue as a going concern beyond one year from the date these financial statements are issued. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Our ability to continue as a going concern and to continue further development of our lead therapeutic candidate, the CardiAMP Cell Therapy System, and our second therapeutic candidate, the CardiALLO Cell Therapy System, through and beyond December 2018, will require us to raise additional capital. We plan to raise additional capital, potentially including debt and equity arrangements, to finance our future operations. If adequate funds are not available, we may be required to reduce operating expenses, delay or reduce the scope of our product development programs, obtain funds through arrangements with others that may require us to relinquish rights to certain of our technologies or products that we would otherwise seek to develop or commercialize ourselves, or cease operations. While we believe we have a viable strategy to raise additional funds, there can be no assurances that we will be able to obtain additional capital on acceptable terms and in the amounts necessary to fully fund our operating needs.

(c)

Use of Estimates

The preparation of the financial statements in accordance with U.S. GAAP requires management to make certain estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ materially from those estimates. Significant items subject to such estimates and assumptions include share-based compensation, the useful lives of property and equipment, allowances for doubtful accounts and sales returns and inventory valuation.

(d)

Principles of Consolidation

The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All intercompany accounts and transactions have been eliminated during the consolidation process.

(e)

Changes to Significant Accounting Policies

Our significant accounting policies are described in Note 2 of the notes to the financial statements included in our Annual Report on Form 10-K filed for the year ended December 31, 2017. Apart from the adoption of ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606) on January 1, 2018 which led to an amended revenue policy, as described in the following paragraphs, there have been no changes to those policies.

Revenue Recognition

Net product revenue – We currently have a portfolio of enabling and delivery products. Revenue from product sales is recognized generally upon shipment to the end customer, which is when control of the product is deemed to be transferred.

Collaboration agreement revenue – Collaboration agreement revenue is income from agreements under partnering programs with corporate and academic institutions, wherein we provide biotherapeutic delivery systems and customer training and support for their use in clinical trials and studies. These programs provide additional clinical data, intellectual property rights and opportunities to participate in the development of combination products for the treatment of cardiac disease.

Revenue is recognized when control of products and services is transferred to the customer in an amount that reflects the consideration that we expect to receive from the customer in exchange for those products and services. This process involves identifying the contract with the customer, determining the performance obligations in the contract, determining the contract price, allocating the contract price to the distinct performance obligations in the contract, and recognizing revenue when the performance obligations have been satisfied. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identifiable from other promises in the contract. We consider a performance obligation satisfied once control of a good or service has been transferred to the customer, meaning the customer has the ability to use and obtain the benefit of the good or service.

Amounts received from customers in advance of revenue recognition are recorded as deferred revenue on the consolidated balance sheets.

(f)

Recently Adopted Accounting Pronouncement

In May 2014, the FASB issued Topic 606, which provides comprehensive guidance for revenue recognition. Topic 606 affects any entity which either enters into contracts with customers to transfer goods or services or enters into contracts for the transfer of nonfinancial assets. The core principle of the guidance provides that a company should recognize revenue when promised goods or services are transferred to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. Additionally, qualitative and quantitative disclosures are required about customer contracts, significant judgments and changes in judgments, and assets recognized from the costs to obtain or fulfill a contract. The new standard can be applied retrospectively to each prior reporting period presented or retrospectively with the cumulative effect of the change recognized at the date of the initial application in retained earnings.

On January 1, 2018, we adopted Topic 606 using the cumulative effect adoption method. Results for reporting periods beginning after January 1, 2018 are presented under Topic 606, while prior period amounts are not adjusted and continue to be reported in accordance with our historic accounting under Topic 605. We recorded a net reduction to opening accumulated deficit of $76,000 as of January 1, 2018 due to the cumulative impact of adopting Topic 606, with the impact related to our collaboration revenues.

In January 2016, the FASB issued ASU No. 2016-01 (ASU 2016-01), Recognition and Measurement of Financial Assets and Financial Liabilities. ASU 2016-01 changes accounting for equity investments, financial liabilities under the fair value option and the presentation and disclosure requirements for financial instruments. In addition, the update clarifies guidance related to the valuation allowance assessment when recognizing deferred tax assets resulting from unrealized losses on available-for-sale debt securities. We adopted ASU 2016-01 on January 1, 2018 and the adoption did not have a material impact on our financial statements.

In May 2017, the FASB issued ASU No. 2017-09 Compensation – Stock Compensation (Topic 718) Scope of Modification Accounting (ASU 2017-09). The amendments in ASU 2017-09 provide guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. We adopted ASU 2017-09 effective January 1, 2018, and the adoption did not have a material impact on our financial statements.

(g)

Recently Issued Accounting Pronouncements

In February 2016, the FASB issued ASU No. 2016-02 Leases (Topic 842) (ASU 2016-02), which supersedes existing guidance on accounting for leases in Leases (Topic 840) and generally requires all leases to be recognized in the consolidated balance sheet. ASU 2016-02 is effective for annual and interim reporting periods beginning after December 15, 2018; early adoption is permitted. We do not plan to elect early adoption. The provisions of ASU 2016-02 are to be applied using a modified retrospective approach, or if we elect we may use a cumulative-effect adjustment to retained earnings as of January 1, 2019. We are currently assessing the future impact of this ASU on our consolidated financial statements.

In June 2018, the FASB issued ASU 2018-07 Compensation – Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting, (ASU 2018-07). ASU 2018-07 expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. The guidance is intended to align the accounting for such payments to nonemployees with the existing requirements for share-based payments granted to employees. ASU 2018-07 is effective for fiscal years beginning after December 15, 2018 and is to be adopted through a cumulative-effect adjustment to retained earnings as of January 1, 2019 for then outstanding share-based payments to nonemployees. We are currently assessing the future impact of this ASU on our consolidated financial statements.

Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, and the American Institute of Certified Public Accountants did not or are not believed by management to have a material impact on the Company’s financial statement presentation or disclosures.

(3)

Fair Value Measurement

The fair value of financial instruments reflects the amounts that the Company estimates to receive in connection with the sale of an asset or paid in connection with the transfer of a liability in an orderly transaction between market participants at the measurement date (exit price). The Company follows a fair value hierarchy that prioritizes the use of inputs used in valuation techniques into the following three levels:

Level 1 – quoted prices in active markets for identical assets and liabilities

Level 2 – observable inputs other than quoted prices in active markets for identical assets and liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities

Level 3 – unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

The following table sets forth the fair value of our financial assets measured on a recurring basis as of June 30, 2018 and December 31, 2017 and indicates the fair value hierarchy utilized to determine such fair value (in thousands).

	As of June 30, 2018

	Level 1		Level 2		Level 3		Total
Assets:
Cash equivalents	$	6,383	$	—	$	—	$	6,383

	As of December 31, 2017
	Level 1		Level 2		Level 3		Total
Assets:
Cash equivalents	$	12,063	$	—	$	—	$	12,063

(4)	Inventories

Inventories are stated at the lower of cost or net realizable value using the average cost method. Inventories consisted of the following (in thousands):

	June 30, 2018		December 31, 2017
Raw materials	$	63	$	70
Work in process		29		92
Finished goods		44		29
Total	$	136	$	191

Write downs for excess or expired inventory are based on management’s estimates of forecasted usage of inventories and are included in cost of goods sold. A significant change in the timing or level of demand for certain products as compared to forecasted amounts may result in recording additional write downs for excess or expired inventory in the future. Charges to cost of goods sold for inventory write-downs, reserve adjustments, scrap, and expired inventories totaled approximately $12,000 and $1,000 for the three months ended June 30, 2018 and 2017 respectively, and $15,000 and $10,000 for the six months ended June 30, 2018 and 2017, respectively.

(5)	Property and Equipment, Net

Property and equipment, net consisted of the following (in thousands):

	June 30, 2018			December 31, 2017
Computer equipment and software	$	114		$	106
Laboratory and manufacturing equipment		471			447
Furniture and fixtures		55			48
Leasehold improvements		326			326
Property and equipment, gross		966			927
Less accumulated depreciation		(802	)		(758	)
Property and equipment, net	$	164		$	169

(6)	Accrued Expenses and Other Current Liabilities

Accrued expenses and other current liabilities consisted of the following (in thousands):

	June 30, 2018		December 31, 2017
Accrued expenses	$	180	$	129
Accrued employee costs		412		410
Grant liability		635		663
Customer deposits		87		61
Total	$	1,314	$	1,263

(7)	Share-Based Compensation

The share-based compensation expense is recorded in cost of goods sold, research and development, and selling, general and administrative expenses based on the employee's respective function. No share-based compensation was capitalized during the periods presented. Share-based compensation expense for the three and six months ended June 30, 2018 and 2017 was recorded as follows (in thousands):

	Three months ended June 30,				Six months ended June 30,
	2018		2017		2018		2017
Cost of goods sold	$	36	$	33	$	66	$	74
Research and development		264		154		461		326
Selling, general and administrative		438		489		826		898
Share-based compensation expense	$	738	$	676	$	1,353	$	1,298

The following table summarizes the activity of stock options and related information:

				Weighted
				average
	Number of			exercise
	shares			price
Balance, December 31, 2017		4,213,100		$	2.96
Stock options granted		1,603,075			2.48
Stock options exercised		(2,488	)		1.80
Stock options cancelled		(135,487	)		2.69
Balance, June 30, 2018		5,678,200		$	2.83

The weighted average grant-date fair value of options granted during the six months ended June 30, 2018 was $1.77 per share.

Employee Share-Based Compensation (Stock Options)

During the six months ended June 30, 2018, we granted stock options to certain non-employee directors and employees to purchase 1,603,075 shares of common stock. The fair value of each option grant was estimated on the date of the grant using the Black-Scholes option pricing model with the following assumptions:

Risk-free interest rate	2.66%	-	2.87%
Volatility		81%
Dividend yield		None
Expected term (in years)		6.25

Unrecognized share-based compensation for employee options as of June 30, 2018 was approximately $6.3 million to be recognized over a remaining weighted average service period of 2.8 years.

Restricted Stock Units (RSUs)

The following summarizes the activity of non-vested RSUs:

				Weighted
				average
				grant date
	Number of			fair value
	shares			per share
Balance, December 31, 2017		97,996		$	8.71
RSUs vested		(57,108	)		7.03
Balance, June 30, 2018		40,888		$	11.04

Unrecognized share-based compensation for employee RSUs granted as of June 30, 2018 was approximately $348,000 to be recognized over a remaining weighted average service period of 1.5 years.

Nonemployee Share-Based Compensation

During the six months ended June 30, 2018, we did not grant any options to purchase shares of common stock to consultants. Options granted to consultants have been granted in exchange for consulting services to be rendered and vest over the term specified in the grant, which correlates to the period the services are rendered. We recorded $31,000 and $277,000 for the three months ended June 30, 2018 and 2017, respectively, and $76,000 and $510,000 for the six months ended June 30, 2018 and 2017, respectively as nonemployee share-based compensation expense.

We account for share-based compensation arrangements with nonemployees, using the Black-Scholes option pricing model, based on the fair value as these instruments vest. Accordingly, at each reporting date, we revalue the unearned portion of the share-based compensation and the resulting change in fair value is recognized in the consolidated statements of operations over the period the related services are rendered. The following assumptions were used to value the awards for the six months ended June 30, 2018:

Risk-free interest rate	2.80%	-	2.84%
Volatility	78%	-	80%
Dividend yield		None
Expected term (in years)	8.1	-	8.8

(8)	Net Loss per Share

Basic net loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding for the period. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common share equivalents outstanding for the period determined using the treasury-stock method. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding since the effects of potentially dilutive securities are antidilutive due to our net loss position.

The following outstanding common stock equivalents were excluded from the computation of diluted net loss per share for the periods presented because including them would have been antidilutive:

	June 30,
	2018		2017
Stock options to purchase common stock		5,678,200		4,008,634
Unvested restricted stock units		40,888		98,000
Total		5,719,088		4,106,634

(9)	Income Taxes

During the six months ended June 30, 2018 and 2017, there was no income tax expense or benefit for federal or state income taxes in the accompanying condensed consolidated statements of operations due to the Company’s net loss and a full valuation allowance on the resulting deferred tax assets.

As of June 30, 2018, we retain a full valuation allowance on our deferred tax assets in all jurisdictions. The realization of our deferred tax assets depends primarily on our ability to generate future taxable income which is uncertain. We do not believe that our deferred tax assets are realizable on a more-likely-than-not basis; therefore, the net deferred tax assets have been fully offset by a valuation allowance.

On December 22, 2017, the Tax Cuts and Jobs Act (H.R. 1) (the Tax Act) was signed into law. The new law resulted in significant changes to the U.S. corporate income tax system. These changes included the reduction of the corporate income tax rate from a maximum rate of 35% to 21% and the elimination or reduction of certain domestic deductions and credits.

The 2017 provisional charge related to the Tax Act was an estimate and the measurement of net deferred tax assets is subject to further analysis and potential correlative adjustments as developing interpretations and guidance from the U.S. Treasury Department, the Internal Revenue Service, and other standard setting bodies provide additional clarifications of the provisions of the Tax Act. Updated guidance and regulations could result in changes to this provisional charge during 2018 when the analysis is complete, and, in accordance with the guidance in Staff Accounting Bulletin 118, we will continue to monitor guidance and make necessary adjustments. No measurement-period adjustments were made during the six months ended June 30, 2018.

(10)	Related Party Transactions

In August 2016, we granted an option to purchase 418,977 shares of common stock, with a four year vesting period and an exercise price of $1.80 per share, to OPKO Health, Inc. (“OPKO”) as consideration for consulting services to be provided by OPKO. We recorded $62,000 and $306,000 as share-based compensation expense related to the OPKO stock option during the six months ended June 30, 2018 and 2017, respectively. The estimated grant-date fair value of the option was $5.3 million. The term of the consulting agreement is four years and will be automatically renewed for successive one year periods. The chairman and chief executive officer of OPKO is a beneficial owner of more than 5% of the outstanding shares of our common stock and OPKO itself is also a beneficial owner of more than 5% of the outstanding shares of our common stock.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion of our financial condition and results of operations should be read in conjunction with our financial statements and related notes included elsewhere in this Quarterly Report on Form 10-Q. This discussion contains certain forward-looking statements that involve risk and uncertainties. Our actual results may differ materially from those discussed below. Factors that could cause or contribute to such differences include, but are not limited to, those listed in our Annual Report on Form 10-K and elsewhere in this report. Historical results are not necessarily indicative of future results.

Overview

We are a clinical-stage regenerative medicine company developing novel therapeutics for cardiovascular diseases with large unmet medical needs. Our lead therapeutic candidate is the investigational CardiAMP Cell Therapy System, which provides an autologous bone marrow derived cell therapy (using a patient’s own cells) for the treatment of two clinical indications: heart failure that develops after a heart attack and chronic myocardial ischemia.

We initiated our United States Food and Drug Administration, or FDA, Phase III pivotal trial for CardiAMP Cell Therapy in ischemic systolic heart failure, in December 2016. The CardiAMP Heart Failure Trial is a Phase III, multi-center, randomized, double-blinded, sham-controlled study of up to 260 patients at 40 centers nationwide, which includes a 10-patient roll-in cohort. The trial’s primary endpoint is a clinical composite of six minute walk distance and major adverse cardiac and cerebrovascular events.

In September 2017, the independent Data Safety Monitoring Board, or DSMB, completed the pre-specified interim analysis of safety outcomes for the first 10 patients treated in the Phase III trial of its investigational CardiAMP cell therapy product. The DSMB indicated there were no significant safety concerns with the CardiAMP study results and recommended that the trial continue, as planned.

CardiAMP Heart Failure efficacy results from the primary endpoint in the open label roll-in cohort are anticipated in the fourth quarter of 2018. An invited viewpoint manuscript containing efficacy data from the roll-in cohort has been accepted to the prestigious Circulation Research journal with an anticipated print release date in September 2018, and potential for earlier online publication. Two related abstracts have been accepted for presentation at the Transcatheter Therapeutics Conference also in September 2018. In Q2 2018 due to retiring staff at the CardiAMP Heart Failure cell potency assay core lab, the lab was unable to accept clinical samples for two months. The core lab staffing issues have been solved and additional laboratory capabilities have been established with an aim to build in redundancy with respect to the performance of the CardiAMP Heart Failure Cell Potency Assay in the future. Currently 17 world class medical centers are actively enrolling in the study. We anticipate that trial enrollment will be completed in Q3 2019.

In January 2018, the FDA approved a second investigational device exemption, or IDE, for the randomized controlled pivotal trial of autologous bone marrow mononuclear cells using the CardiAMP Cell Therapy System in patients with refractory chronic myocardial ischemia for up to 343 patients at up to 40 clinical sites in the United States, the “CardiAMP Chronic Myocardial Ischemia Trial”. This therapeutic approach uses many of the same novel aspects as the CardiAMP Heart Failure Trial and leverages our experience and investment in the heart failure trial. We anticipate dosing the first patient in Q1 2019.

The Department of Health & Human Services Centers for Medicare & Medicaid Services, or CMS, has designated that both the CardiAMP Heart Failure Trial and the CardiAMP Chronic Myocardial Ischemia Trial qualify for Medicare national coverage. Covered costs are anticipated to include patient screening, the CardiAMP Cell Therapy System and procedure, and clinical follow-up at one and two years after the procedure. Private insurance plans covering 50 million insured Americans follow this CMS reimbursement policy, and are similarly anticipated to cover these costs.

Our second therapeutic candidate is the CardiALLO Cell Therapy System, an investigational culture expanded donor bone marrow derived “off the shelf” mesenchymal stem cell therapy initially to treat heart failure. We anticipate submitting an Investigational New Drug, or IND, application to the FDA for a Phase II trial for CardiALLO Cell Therapy System for the treatment of ischemic systolic heart failure in Q4 2018. This IND is expected to have improved chemistry manufacturing controls relative to our previous co-sponsored clinical investigations utilizing donor bone marrow derived “off the shelf” mesenchymal stem cells.

To date, we have devoted substantially all our resources to research and development efforts relating to our therapeutic candidates and biotherapeutic delivery systems, including conducting clinical trials, developing manufacturing and sales capabilities, in-licensing related intellectual property, providing general and administrative support for these operations and protecting our intellectual property. We have generated modest revenues from sales of our approved products. We have funded our operations primarily through the sales of equity and convertible debt securities, and certain government and private grants.

We have incurred net losses in each year since our inception. Our net losses were approximately $6.8 million and $5.8 million for the six months ended June 30, 2018 and 2017, respectively. As of June 30, 2018, we had an accumulated deficit of approximately $79.2 million. Substantially all our net losses have resulted from costs incurred in connection with our research and development programs, clinical trials, intellectual property matters, building our manufacturing and sales capabilities, and from general and administrative costs associated with our operations. As discussed in more detail under “Liquidity and Capital Resources”, we believe our cash and cash equivalents as of June 30, 2018 are sufficient to fund our operations into December 2018. As a result there is substantial doubt about our ability to continue as a going concern within one year after the date these financial statements are issued. We plan to raise additional capital, potentially including debt and equity arrangements, to finance our future operations.

Financial Overview

Revenue

We currently have a portfolio of enabling and delivery products, from which we have generated modest revenue.

Cost of Goods Sold

Cost of goods sold includes the costs of raw materials and components, manufacturing personnel and facility costs and other indirect and overhead costs associated with manufacturing our enabling and delivery products.

Research and Development Expenses

Our research and development expenses consist primarily of:

•

salaries and related overhead expenses, which include share-based compensation and benefits for personnel in research and development functions;

•

fees paid to consultants and contract research organizations, or CROs, including in connection with our preclinical studies and clinical trials and other related clinical trial fees, such as for investigator grants, patient screening, laboratory work, clinical trial management and statistical compilation and analysis;

•

costs related to acquiring and manufacturing clinical trial materials;

•

costs related to compliance with regulatory requirements; and

•

payments related to licensed products and technologies.

We expense all research and development costs in the periods in which they are incurred. Costs for certain development activities are recognized based on an evaluation of the progress of completion of specific tasks using information and data provided to us by our vendors and clinical sites. Nonrefundable advance payments for goods or services to be received in future periods for use in research and development activities are deferred and capitalized. The capitalized amounts are then expensed as the related goods are delivered and the services are performed.

We plan to increase our research and development expenses for the foreseeable future as we continue the pivotal CardiAMP Heart Failure Trial, advance the pivotal CardiAMP Chronic Myocardial Ischemia Trial, further develop the CardiAMP and CardiALLO Cell Therapy Systems, and subject to the availability of additional funding, develop other therapeutic candidates for additional indications. We typically use our employee and infrastructure resources across multiple research and development programs, and accordingly, we have not historically allocated resources specifically to our individual programs.

Selling, General and Administrative Expenses

Selling, general and administrative expenses consist primarily of salaries and related costs for employees in executive, finance and administration, sales, corporate development and administrative support functions, including share-based compensation expenses and benefits. Other selling, general and administrative expenses include sales commissions, rent, accounting and legal services, obtaining and maintaining patents, the cost of consultants, occupancy costs, insurance premiums and information systems costs.

Other Income (Expense)

Other income and expense consists primarily of interest income we earn on our cash, cash equivalents and investments.

Critical Accounting Policies and Estimates

Our management’s discussion and analysis of our financial condition and results of operations is based on our financial statements, which we have prepared in accordance with generally accepted accounting principles in the United States. The preparation of our financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities. We evaluate these estimates and judgments on an ongoing basis. We base our estimates on historical experience and on various judgements that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not clear from other sources. Actual results may differ from these estimates under different assumptions or conditions.

Apart from the adoption of ASU No. 2014-09 Revenue from Contracts with Customers (Topic 606) on January 1, 2018, which led to an amended revenue policy described below, there were no material changes during the six months ended June 30, 2018 in our critical accounting estimates or accounting policies described in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K.

Revenue Recognition

Amounts received from customers in advance of revenue recognition are recorded as deferred revenue on the consolidated balance sheets.

Results of Operations

Comparison of Three Months Ended June 30, 2018 and 2017

The following table summarizes our results of operations for the three months ended June 30, 2018 and 2017 (in thousands):

	Three months ended June 30,
	2018			2017
Revenue:
Net product revenue	$	89		$	101
Collaboration agreement revenue		150			11
Total revenue		239			112
Costs and expenses:
Cost of goods sold		135			203
Research and development		2,031			1,295
Selling, general and administrative		1,325			1,582
Total costs and expenses		3,491			3,080
Operating loss		(3,252	)		(2,968	)
Other income (expense):
Interest income		35			23
Other expense		—			—
Total other income, net		35			23
Net loss	$	(3,217	)	$	(2,945	)

Revenue. Revenue increased by $127,000 in the three months ended June 30, 2018 compared to the three months ended June 30, 2017 primarily due to increased revenue earned under programs with our collaborative partners after the adoption of Topic 606. We expect overall sales volumes to increase in 2018 as compared to 2017, resulting in moderate growth in net product revenue year over year.

Cost of Goods Sold. Cost of goods sold decreased by $68,000 in the three months ended June 30, 2018 compared to the three months ended June 30, 2017 primarily due to a decrease in product sales volumes coupled with improved productivity and reduced materials costs for routine manufacturing testing. We expect cost of goods sold to increase moderately in 2018 due to growth in net product revenues during the latter half of the year.

Research and Development Expenses. Research and development expenses increased by $736,000 in the three months ended June 30, 2018 compared to the three months ended June 30, 2017 primarily due to increased expenses incurred in conducting the ongoing pivotal CardiAMP Heart Failure Trial and in the development of the CardiALLO Cell Therapy System. These expenses include fees paid to consultants and CROs and additional personnel costs. We expect research and development expenses to continue to increase as enrollment accelerates in the CardiAMP Heart Failure Trial and we further develop the CardiAMP and CardiALLO cell therapy platforms.

Selling, General and Administrative Expenses. Selling, general and administrative expenses for the three months ended June 30, 2018 totaled $1,325,000 which was a 16.2% decrease as compared to $1,582,000 for three months ended June 30, 2017, due primarily to lower stock compensation expense. We expect selling, general and administrative expenses for 2018 to increase moderately in the latter half of 2018 compared to 2017, as we continue to enhance and strengthen the supporting staff and infrastructure needed to support the CardiAMP Heart Failure Trial and development of our therapeutic programs.

Comparison of Six Months Ended June 30, 2018 and 2017

The following table summarizes our results of operations for the six months ended June 30, 2018 and 2017 (in thousands):

	Six months ended June 30,
	2018			2017
Revenue:
Net product revenue	$	171		$	210
Collaboration agreement revenue		267			39
Total revenue		438			249
Costs and expenses:
Cost of goods sold		292			378
Research and development		3,986			2,328
Selling, general and administrative		3,032			3,386
Total costs and expenses		7,310			6,092
Operating loss		(6,872	)		(5,843	)
Other income (expense):
Interest income		71			23
Other expense		—			(1	)
Total other income, net		71			22
Net loss	$	(6,801	)	$	(5,821	)

Revenue. Revenue increased by $189,000 in the six months ended June 30, 2018 compared to the six months ended June 30, 2017 primarily due to increased revenue earned under programs with our collaborative partners after the adoption of Topic 606.

Cost of Goods Sold. Cost of goods sold decreased by $86,000 in the six months ended June 30, 2018 compared to the six months ended June 30, 2017 primarily due to a decrease in product sales volumes coupled with improved productivity and reduced materials costs for routine manufacturing testing.

Research and Development Expenses. Research and development expenses increased by $1,658,000 in the six months ended June 30, 2018 compared to the six months ended June 30, 2017 primarily due to increased expenses incurred in conducting the ongoing pivotal CardiAMP Heart Failure Trial and in the development of the CardiALLO Cell Therapy System. These expenses include fees paid to consultants and CROs and additional personnel costs. We expect research and development expenses to continue to increase as enrollment accelerates in the CardiAMP Heart Failure Trial and we further develop the CardiAMP and CardiALLO platforms.

Selling, General and Administrative Expenses. Selling, general and administrative expenses for the six months ended June 30, 2018 totaled $3,032,000 , which was a 10.5% decrease as compared to $3,386,000 for six months ended June 30, 2017, due primarily to lower stock compensation expense. We expect selling, general and administrative expenses for 2018 to increase moderately in the latter half of 2018 compared to 2017, as we continue to enhance and strengthen the supporting staff and infrastructure needed to support the CardiAMP Heart Failure Trial and development of our therapeutic programs.

Liquidity and Capital Resources

We have incurred net losses each year since our inception and as of June 30, 2018, we had an accumulated deficit of approximately $79.2 million. We anticipate that we will continue to incur net losses for the next several years.

We have funded our operations principally through the sales of equity and convertible debt securities as well as the cash acquired through the reverse merger transaction completed on October 24, 2016. As of June 30, 2018, we had cash and cash equivalents of approximately $6.8 million.

The following table shows a summary of our cash flows for the periods indicated (in thousands):

	Six months ended June 30,
	2018			2017
Net cash provided by (used in):
Operating activities	$	(5,814	)	$	(4,369	)
Investing activities		(46	)		(1,896	)
Financing activities		5			22
Net decrease in cash and cash equivalents	$	(5,855	)	$	(6,243	)

Cash Flows from Operating Activities. The increase in cash used in operating activities of $1,445,000 in the six months ended June 30, 2018 compared to the six months ended June 30, 2017 related primarily to increased cash outflows to conduct the pivotal CardiAMP Heart Failure Trial, further develop the CardiAMP and CardiALLO cell therapy programs and to build the supporting infrastructure to sustain these efforts and support operations as a public company. We expect spending to increase in 2018 as compared to 2017 as we continue enrolling and treating patients in the CardiAMP Heart Failure Trial, further develop the CardiAMP and CardiALLO Cell Therapy Systems and continue to strengthen and enhance the supporting organization.

Cash Flows from Investing Activities. Net cash used in investing activities of $46,000 during the six months ended June 30, 2018 consisted of the purchases of property and equipment.

Cash Flows from Financing Activities. Net cash provided by financing activities of $5,000 during the six months ended June 30, 2018 consisted of the proceeds from the exercise of stock options.

Future Funding Requirements

To date, we have generated modest revenue from sales of our approved products. We do not know when, or if, we will generate any revenue from our development stage biotherapeutic programs. We do not expect to generate any revenue from sales of our CardiAMP or CardiALLO therapeutic candidates unless and until we obtain regulatory approval. At the same time, we expect our expenses to increase in connection with our ongoing development activities, particularly as we continue the research, development and clinical trials of, and seek regulatory approval for, our therapeutic candidates. In addition, subject to obtaining regulatory approval for any of our therapeutic and companion diagnostic candidates, we expect to incur significant commercialization expenses for product sales, marketing, manufacturing and distribution. We anticipate that we will need additional funding in connection with our continuing operations.

Based upon our current operating plan, we believe that the cash and cash equivalents of $6.8 million as of June 30, 2018 are sufficient to fund our operations into December 2018. In order to continue to further the development of our lead therapeutic candidates, the CardiAMP Cell Therapy System, and our second therapeutic candidate, the CardiALLO Cell Therapy System, through and beyond December 2018, we will be required to raise additional capital. We plan to raise additional capital, potentially including debt and equity arrangements, to finance our future operations. We have based our estimates on assumptions that may prove to be wrong, and we may use our available capital resources sooner than we currently expect. Because of the numerous risks and uncertainties associated with the development and commercialization of our therapeutic candidates, we are unable to estimate the amounts of increased capital outlays and operating expenditures necessary to complete the development of our therapeutic candidates.

Our future capital requirements will depend on many factors, including:

•

the progress, costs, results and timing of our CardiAMP and CardiALLO clinical trials and related development programs;

•

FDA acceptance of our CardiAMP and CardiALLO therapies for heart failure and for other potential indications;

•

the outcome, costs and timing of seeking and obtaining FDA and any other regulatory approvals;

•

the costs associated with securing, establishing and maintaining commercialization and manufacturing capabilities;

•

the number and characteristics of product candidates that we pursue, including our product candidates in preclinical development;

•

the ability of our product candidates to progress through clinical development successfully;

•

our need to expand our research and development activities;

•

the costs of acquiring, licensing or investing in businesses, products, product candidates and technologies;

•

our ability to maintain, expand and defend the scope of our intellectual property portfolio, including the amount and timing of any payments we may be required to make, or that we may receive, in connection with the licensing, filing, prosecution, defense and enforcement of any patents or other intellectual property rights;

•

the general and administrative expenses related to being a public company;

•

our need and ability to hire additional management and scientific, medical and sales personnel;

•

the effect of competing technological and market developments; and

•

our need to implement additional internal systems and infrastructure, including financial and reporting systems.

Until such time that we can generate meaningful revenue from the sales of approved therapies and products, if ever, we expect to finance our operating activities through public or private equity or debt financings, government or other third-party funding, marketing and distribution arrangements, and other collaborations, strategic alliances and licensing arrangements or a combination of these approaches. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interests of our Common Stock holders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our Common Stock holders. Debt financing, if available, may involve agreements that include conversion discounts or covenants limiting or restricting our ability to take specific actions, such as incurring debt, making capital expenditures or declaring dividends. If we raise additional funds through government or other third-party funding, marketing and distribution arrangements or other collaborations, or strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs, products or therapeutic candidates or to grant licenses on terms that may not be favorable to us.

Our condensed consolidated financial statements as of and for the three months ended June 30, 2018 have been prepared on the basis that we will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. Due to the factors described above, there is substantial doubt about our ability to continue as a going concern within one year after the date these financial statements are issued. Our ability to continue as a going concern will depend in a large part, on our ability to raise additional capital. If adequate funds are not available, we may be required to reduce operating expenses, delay or reduce the scope of our product development programs, obtain funds through arrangements with others that may require us to relinquish rights to certain of our technologies or products that we would otherwise seek to develop or commercialize ourselves, or cease operations. While we believe we have a viable strategy to raise additional funds, there can be no assurances that we will be able to obtain additional capital on acceptable terms and in the amounts necessary to fully fund our operating needs.

The financial statements do not include any adjustments that might result from the outcome of this uncertainty. If we are unable to continue as a going concern, we may be forced to liquidate assets. In such a scenario, the values received for assets in liquidation or dissolution could be significantly lower than the values reflected in our financial statements.

Off-Balance Sheet Arrangements

During the periods presented, we did not have, nor do we currently have, any off-balance sheet arrangements as defined under the rules of the Securities and Exchange Commission.

Recent Accounting Pronouncements

See Note 2 of our notes to condensed consolidated financial statements for information regarding recent accounting pronouncements that are of significance or potential significance to us.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

There have been no material changes in our market risks during the quarter ended June 30, 2018.

Our exposure to market risk is currently limited to our cash and cash equivalents, all of which have maturities of less than three months. The goals of our investment policy are preservation of capital, maintenance of liquidity needs, and fiduciary control of cash and investments. We also seek to maximize income from our investments without assuming significant risk or departing from our investment policy. We currently do not hedge interest rate exposure. Because of the short-term nature of our cash equivalents, we do not believe that an increase in market rates would have a material negative impact on the value of our portfolio.

Interest Rate Risk

As of June 30, 2018, based on current interest rates and total borrowings outstanding, a hypothetical 100 basis point increase or decrease in interest rates would have an immaterial pre-tax impact on our results of operations.

Foreign Currency Exchange Risks

We are a U.S. entity and our functional currency is the U.S. dollar. The vast majority of our revenues were derived from sales in the United States. We have business transactions in foreign currencies, however, we believe we do not have significant exposure to risk from changes in foreign currency exchange rates at this time. We do not currently engage in hedging or similar transactions to reduce our foreign currency risks. We will continue to monitor and evaluate our internal processes relating to foreign currency exchange, including the potential use of hedging strategies.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports under the Exchange Act, is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, as our controls are designed to do, and management necessarily was required to apply its judgment in evaluating the risk related to controls and procedures.

In connection with the preparation of this Quarterly Report on Form 10-Q, as of June 30, 2018, an evaluation was performed under the supervision and with the participation of our management, including the Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Exchange Act). Based on that evaluation, our Chief Executive Officer and our Chief Financial Officer have concluded that, as of June 30, 2018, our disclosure controls and procedures were, in design and operation, effective.

Changes in Internal Control over Financial Reporting

There were no changes to our internal control over financial reporting identified in connection with the evaluation required by rule 13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the quarter ended June 30, 2018 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

We may be subject to various claims, complaints, and legal actions that arise from time to time in the normal course of business. Management does not believe that we are a party to any currently pending legal proceedings. There can be no assurance that existing or future legal proceedings arising in the ordinary course of business or otherwise will not have a material adverse effect on our business, financial position, results of operations, or cash flows.

ITEM 1A. RISK FACTORS

In addition to the other information set forth in this report, you should carefully consider the factors discussed in Part I, “Item 1A. Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2017, which could materially affect our business, financial condition, or future results. The risks described in this report and in our Annual Report on 10-K are not the only risks facing our company. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition or future results.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5. OTHER INFORMATION

None.

ITEM 6. EXHIBIT INDEX

The exhibits listed in the Exhibit Index to this Quarterly Report on Form 10-Q are incorporated herein by reference.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	BIOCARDIA, INC. (Registrant)


Date: August 9, 2018	By:	/s/ Peter Altman
		Peter Altman
		President and Chief Executive Officer
		(Principal Executive Officer)

Date: August 9, 2018	By:	/s/ David McClung
		David McClung
		Chief Financial Officer
		(Principal Financial and Accounting Officer)

EXHIBIT INDEX

Exhibit

Number

Exhibit Description

31.1*

Certification of Principal Executive Officer under Section 302 of the Sarbanes-Oxley Act of 2002.

31.2*

Certification of Principal Financial Officer under Section 302 of the Sarbanes-Oxley Act of 2002.

32.1**

Certification of Principal Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2**

Certification of Principal Financial Officer Pursuant to Rule 13a-14(b) and Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS+	XBRL Instance Document
101.SCH+	XBRL Taxonomy Extension Schema Document
101.CAL+	XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF+	XBRL Taxonomy Extension Definition Linkbase Document
101.LAB+	XBRL Taxonomy Extension Label Linkbase Document
101.PRE+	XBRL Taxonomy Extension Presentation Linkbase Document

*	Filed herewith.

**	Furnished herewith.

+	The financial information contained in these XBRL documents is unaudited and is furnished, not filed with the Securities and Exchange Commission.

EX-31.1 2 ex_120004.htm EXHIBIT 31.1 ex_120004.htm

Exhibit 31.1

Certification of Principal Executive Officer

Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

I, Peter Altman, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of BioCardia, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)

Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)

Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: August 9, 2018

/s/ Peter Altman

Name: Peter Altman

Title: President and Chief Executive Officer

(Principal Executive Officer)

EX-31.2 3 ex_120005.htm EXHIBIT 31.2 ex_120005.htm

Exhibit 31.2

Certification of Principal Financial Officer

Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

I, David McClung, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of BioCardia, Inc.;

(a)

(b)

(c)

(d)

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: August 9, 2018

/s/ David McClung

Name: David McClung

Title: Chief Financial Officer

(Principal Financial Officer)

EX-32.1 4 ex_120006.htm EXHIBIT 32.1 ex_120006.htm

Exhibit 32.1

Certification of Principal Executive Officer

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, I, Peter Altman, the President and Chief Executive Officer of BioCardia, Inc. (the "Company"), hereby certify, that, to my knowledge:

1. The Quarterly Report on Form 10-Q for the period ended June 30, 2018 (the "Report") of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: August 9, 2018

/s/ Peter Altman

Name: Peter Altman

Title: President and Chief Executive Officer

(Principal Executive Officer)

EX-32.2 5 ex_120007.htm EXHIBIT 32.2 ex_120007.htm

Exhibit 32.2

Certification of Principal Financial Officer

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, I, David McClung, the Chief Financial Officer of BioCardia, Inc. (the “Company”), hereby certify, that, to my knowledge:

1. The Quarterly Report on Form 10-Q for the period ended June 30, 2018 (the “Report”) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: August 9, 2018

/s/ David McClung

Name: David McClung

Title: Chief Financial Officer

(Principal Financial Officer)

EX-101.INS 6 bcda-20180630.xml XBRL INSTANCE DOCUMENT <div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: top;"> <td style="width: 27pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;">(</div><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6</div></div><div style="display: inline; font-weight: bold;">)</div></div> </td> <td> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;">Accrued </div><div style="display: inline; font-weight: bold;">Expenses and Other Current </div><div style="display: inline; font-weight: bold;">Liabilities</div></div> </td> </tr> </table> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:27pt;margin-right:0pt;margin-top:0pt;text-align:justify;">Accrued expenses and other current liabilities consisted of the following (in thousands):</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">  </div> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin-right: 10%; margin-left: 27pt; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td colspan="1" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 66%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">June 30,<br /> 2018</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31,<br /> 2017</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 66%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Accrued expenses</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">180</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">129</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255);"> <td colspan="1" style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 66%;">Accrued employee costs</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">412</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">410</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 66%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Grant liability</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">635</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">663</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 66%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Customer deposits</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">87</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">61</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 66%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Total</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,314</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,263</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </table> </div></div> 1314000 1263000 P4Y P1Y <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="; text-indent: 0px; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"><tr style="vertical-align: top;"><td style="width: 36pt;"></td> <td style="width: 18pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">(b)</div></div></div> </td> <td> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Liquidity</div></div></div> </td> </tr> </table> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:20.25pt;margin-right:0pt;margin-top:0pt;text-align:left;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:justify;">We have incurred net losses and negative cash flows from operations since our inception and had an accumulated deficit of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$79.2</div> million as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30, 2018. </div>Management expects operating losses and negative cash flows to continue through the next several years. Based on management’s current plans, management believes cash and cash equivalents of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$6.8</div> million as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30, 2018 </div>are sufficient to fund us into <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 2018. </div>These factors raise substantial doubt about our ability to continue as a going concern beyond <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> year from the date these financial statements are issued. The financial statements do <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> include any adjustments that might result from the outcome of this uncertainty.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:justify;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:justify;">Our ability to continue as a going concern and to continue further development of our lead therapeutic candidate, the CardiAMP Cell Therapy System, and our <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">second</div> therapeutic candidate, the CardiALLO Cell Therapy System, through and beyond <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 2018, </div>will require us to raise additional capital. We plan to raise additional capital, potentially including debt and equity arrangements, to finance our future operations. If adequate funds are <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> available, we <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>be required to reduce operating expenses, delay or reduce the scope of our product development programs, obtain funds through arrangements with others that <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>require us to relinquish rights to certain of our technologies or products that we would otherwise seek to develop or commercialize ourselves, or cease operations. While we believe we have a viable strategy to raise additional funds, there can be <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> assurances that we will be able to obtain additional capital on acceptable terms and in the amounts necessary to fully fund our operating needs. </div></div></div> 635000 663000 0.05 0.05 <div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="margin-right: 10%; margin-left: 27pt; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td colspan="1" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 66%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">June 30,<br /> 2018</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31,<br /> 2017</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 66%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Accrued expenses</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">180</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">129</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255);"> <td colspan="1" style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 66%;">Accrued employee costs</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">412</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">410</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 66%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Grant liability</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">635</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">663</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 66%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Customer deposits</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">87</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">61</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 66%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Total</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,314</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,263</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </table></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="margin-right: 5%; margin-left: 27pt; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td colspan="1" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 48%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Three months ended June 30,</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Six months ended June 30,</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td colspan="1" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 48%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2018</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2017</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2018</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2017</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 48%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Cost of goods sold</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">36</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">33</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">66</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">74</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 48%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Research and development</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">264</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">154</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">461</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">326</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 48%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Selling, general and administrative</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">438</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">489</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">826</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">898</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 48%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Share-based compensation expense</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">738</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">676</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,353</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,298</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </table></div> 5300000 false --12-31 Q2 2018 2018-06-30 10-Q 0000925741 38277908 Yes Accelerated Filer BioCardia, Inc. No No bcda

505000

902000

191000

95000

180000

129000

802000

758000

84895000

83537000

31000

277000

76000

510000

62000

306000

36000

33000

66000

74000

264000

154000

461000

326000

438000

489000

826000

898000

738000

676000

1353000

1298000

3000

6000

5678200

4008634

40888

98000

5719088

4106634

7661000

13538000

7443000

13315000

6834000

12689000

21352000

15109000

6383000

12063000

-5855000

-6243000

0.001

100000000

38277908

38218660

38277908

38218660

38000

135000

203000

292000

378000

3491000

3080000

7310000

6092000

87000

61000

84000

81000

167000

44000

36000

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="; text-indent: 0px; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr style="vertical-align: top;"> <td style="width: 27pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;">(</div><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7</div></div><div style="display: inline; font-weight: bold;">)</div></div> </td> <td> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;">Share-Based Compensation</div></div> </td> </tr> </table> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:27pt;margin-right:0pt;margin-top:0pt;text-align:justify;">The share-based compensation expense is recorded in cost of goods sold, research and development, and selling, general and administrative expenses based on the employee's respective function. <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No</div></div></div></div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"></div> share-based compensation was capitalized during the periods presented. Share-based compensation expense for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">six</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30, 2018 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> was recorded as follows (in thousands):</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">  </div> <div> <table style="margin-right: 5%; margin-left: 27pt; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr style="vertical-align: bottom;"> <td colspan="1" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 48%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Three months ended June 30,</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Six months ended June 30,</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td colspan="1" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 48%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2018</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2017</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2018</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2017</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 48%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Cost of goods sold</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">36</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">33</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">66</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">74</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 48%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Research and development</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">264</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">154</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">461</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">326</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 48%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Selling, general and administrative</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">438</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">489</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">826</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">898</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 48%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Share-based compensation expense</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">738</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">676</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,353</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,298</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> </table> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:27pt;margin-right:0pt;margin-top:0pt;text-align:justify;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:27pt;margin-right:0pt;margin-top:0pt;text-align:justify;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:27.35pt;margin-right:0pt;margin-top:0pt;text-align:justify;">The following table summarizes the activity of stock options and related information:</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:27.35pt;margin-right:0pt;margin-top:0pt;text-align:justify;"> </div> <div> <table style="margin-right: 10%; margin-left: 27pt; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr style="vertical-align: bottom;"> <td colspan="1" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 66%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Weighted</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td colspan="1" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 66%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">average</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td colspan="1" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 66%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Number of</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">exercise</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td colspan="1" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 66%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">shares</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">price</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 66%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Balance, December 31, 2017</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,213,100</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.96</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 66%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Stock options granted</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,603,075</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.48</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 66%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Stock options exercised</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(2,488</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.80</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 66%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Stock options cancelled</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(135,487</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.69</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 66%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Balance, June 30, 2018</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,678,200</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.83</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> </table> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:27pt;margin-right:0pt;margin-top:0pt;text-align:justify;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:27pt;margin-right:0pt;margin-top:0pt;text-align:justify;">The weighted average grant-date fair value of options granted during the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">six</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30, 2018 </div>was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.77</div> per share.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:27pt;margin-right:0pt;margin-top:0pt;text-align:justify;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:27pt;margin-right:0pt;margin-top:0pt;text-align:justify;"><div style="display: inline; font-style: italic;">Employee Share-Based Compensation (Stock Options)</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:27pt;margin-right:0pt;margin-top:0pt;text-align:justify;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:27pt;margin-right:0pt;margin-top:0pt;text-align:justify;">During the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">six</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30, 2018, </div>we granted stock options to certain non-employee directors and employees to purchase <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,603,075</div> shares of common stock. The fair value of each option grant was estimated on the date of the grant using the Black-Scholes option pricing model with the following assumptions:  </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:27pt;margin-right:0pt;margin-top:0pt;text-align:justify;"> </div> <div> <table style="margin-right: 15%; margin-left: 27pt; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 81%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Risk-free interest rate</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 6%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: right;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.66%</div></td> <td style="width: 4%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 6%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.87%</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 81%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Volatility</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 6%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="width: 4%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">81%</div></td> <td style="width: 6%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 81%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Dividend yield</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"> </div> </td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 6%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 4%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">None</div></td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 6%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 81%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Expected term (in years)</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 6%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="width: 4%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6.25</div></td> <td style="width: 6%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> </table> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:27pt;margin-right:0pt;margin-top:0pt;text-align:justify;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:27pt;margin-right:0pt;margin-top:0pt;text-align:justify;">Unrecognized share-based compensation for employee options as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30, 2018 </div>was approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$6.3</div> million to be recognized over a remaining weighted average service period of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.8</div> years.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:27pt;margin-right:0pt;margin-top:0pt;text-align:justify;"> </div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:27.35pt;margin-right:0pt;margin-top:0pt;text-align:justify;"><div style="display: inline; font-style: italic;">Restricted Stock Units</div><div style="display: inline; font-style: italic;"> (RSUs)</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:27.35pt;margin-right:0pt;margin-top:0pt;text-align:justify;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:27.35pt;margin-right:0pt;margin-top:0pt;text-align:justify;">The following summarizes the activity of non-vested RSUs:</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:27.35pt;margin-right:0pt;margin-top:0pt;text-align:justify;"> </div> <div> <table style="margin-right: 10%; margin-left: 27pt; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr style="vertical-align: bottom;"> <td colspan="1" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 66%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Weighted</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td colspan="1" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 66%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">average</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td colspan="1" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 66%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">grant date</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td colspan="1" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 66%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Number of</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">fair value</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td colspan="1" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 66%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">shares</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">per share</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 66%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Balance, December 31, 2017</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">97,996</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8.71</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 66%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">RSUs vested</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(57,108</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7.03</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 66%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Balance, June 30, 2018</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">40,888</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11.04</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> </table> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:27.35pt;margin-right:7.2pt;margin-top:0pt;text-align:justify;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:27.35pt;margin-right:7.2pt;margin-top:0pt;text-align:justify;">Unrecognized share-based compensation for employee RSUs granted as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30, 2018 </div>was approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$348,000</div> to be recognized over a remaining weighted average service period of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.5</div> years.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> <div style=" background-color:#FFFFFF;font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:27pt;margin-right:0pt;margin-top:0pt;text-align:justify;"><div style="display: inline; font-style: italic;">Nonemployee Share-Based Compensation</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:27pt;margin-right:0pt;margin-top:0pt;text-align:justify;">During the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">six</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30, 2018, </div>we did <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> grant any options to purchase shares of common stock to consultants. Options granted to consultants have been granted in exchange for consulting services to be rendered and vest over the term specified in the grant, which correlates to the period the services are rendered. We recorded <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$31,000</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$277,000</div> for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30, 2018 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017,</div> respectively, and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$76,000</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$510,000</div> for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">six</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30, 2018 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017,</div> respectively as nonemployee share-based compensation expense.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:27pt;margin-right:0pt;margin-top:0pt;text-align:left;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:27pt;margin-right:0pt;margin-top:0pt;text-align:justify;">We account for share-based compensation arrangements with nonemployees, using the Black-Scholes option pricing model, based on the fair value as these instruments vest. Accordingly, at each reporting date, we revalue the unearned portion of the share-based compensation and the resulting change in fair value is recognized in the consolidated statements of operations over the period the related services are rendered. The following assumptions were used to value the awards for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">six</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30, 2018:</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:27pt;margin-right:0pt;margin-top:0pt;text-align:justify;"> </div> <div> <table style="margin-right: 15%; margin-left: 27pt; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 81%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Risk-free interest rate</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 6%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: right;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.80%</div></td> <td style="width: 4%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 6%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.84%</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 81%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Volatility</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 6%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: right;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">78%</div></td> <td style="width: 4%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 6%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">80%</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 81%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Dividend yield</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"> </div> </td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 6%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 4%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">None</div></td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 6%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 81%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Expected term (in years)</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 6%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: right;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8.1</div></td> <td style="width: 4%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 6%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8.8</div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;" nowrap="nowrap"> </td> </tr> </table> </div></div>

-0.08

-0.18

-0.15

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: top;"> <td style="width: 27pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;">(</div><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8</div></div><div style="display: inline; font-weight: bold;">)</div></div> </td> <td> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;">Net Loss per Share</div></div> </td> </tr> </table> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:27pt;margin-right:0pt;margin-top:0pt;text-align:left;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:27pt;margin-right:0pt;margin-top:0pt;text-align:left;">Basic net loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding for the period. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common share equivalents outstanding for the period determined using the treasury-stock method. For all periods presented, there is <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> difference in the number of shares used to calculate basic and diluted shares outstanding since the effects of potentially dilutive securities are antidilutive due to our net loss position.  </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36pt;margin-right:0pt;margin-top:0pt;text-align:left;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:27pt;margin-right:0pt;margin-top:0pt;text-align:left;">The following outstanding common stock equivalents were excluded from the computation of diluted net loss per share for the periods presented because including them would have been antidilutive:</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:27pt;margin-right:0pt;margin-top:0pt;text-align:left;"> </div> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin-right: 5%; margin-left: 27pt; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td colspan="1" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">June 30,</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td colspan="1" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2018</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2017</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 68%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Stock options to purchase common stock</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,678,200</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,008,634</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 68%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Unvested restricted stock units</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">40,888</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">98,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 68%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Total</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,719,088</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,106,634</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </table> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:27pt;margin-right:0pt;margin-top:0pt;text-align:left;"><div style="display: inline; font-weight: bold;"> </div></div></div>

0.35

0.21

412000

410000

P2Y292D

P1Y182D

348000

6300000

-390000

60000

96000

68000

25000

16000

3000

12000

-65000

82000

-55000

58000

-58000

-74000

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: top;"> <td style="width: 27pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;">(</div><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4</div></div><div style="display: inline; font-weight: bold;">)</div></div> </td> <td> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-weight: bold;">Inventories</div></div> </td> </tr> </table> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:27pt;margin-right:0pt;margin-top:0pt;text-align:justify;">Inventories are stated at the lower of cost or net realizable value using the average cost method. Inventories consisted of the following (in thousands):</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">  </div> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin-right: 20%; margin-left: 27pt; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td colspan="1" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 62%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">June 30,<br /> 2018</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31, </div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2017</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 62%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Raw materials</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">63</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">70</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 62%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Work in process</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">29</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">92</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 62%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Finished goods</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">44</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">29</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 62%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Total</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">136</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">191</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </table> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:27pt;margin-right:0pt;margin-top:0pt;text-align:justify;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:27pt;margin-right:0pt;margin-top:0pt;text-align:justify;">Write downs for excess or expired inventory are based on management’s estimates of forecasted usage of inventories and are included in cost of goods sold. A significant change in the timing or level of demand for certain products as compared to forecasted amounts <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>result in recording additional write downs for excess or expired inventory in the future. Charges to cost of goods sold for inventory write-downs, reserve adjustments, scrap, and expired inventories totaled approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$12,000</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1,000</div> for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30, 2018 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> respectively, and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$15,000</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$10,000</div> for the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">six</div> months ended <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 30, 2018 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017,</div> respectively.</div></div>

44000

29000

136000

191000

63000

70000

29000

92000

12000

1000

15000

10000

1903000

2413000

7661000

13538000

1819000

2332000

5000

22000

-46000

-1896000

-5814000

-4369000

-3217000

-2945000

-6801000

-5821000

<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="; text-indent: 0px; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"><tr style="vertical-align: top;"><td style="width: 18pt;"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">(</div></div><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">f</div></div><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">)</div></div></div> </td> <td> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Recently Adopted Accounting Pronouncement</div></div></div> </td> </tr> </table> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:58.5pt;margin-right:0pt;margin-top:0pt;text-align:left;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 54pt; text-align: justify;">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> May 2014, </div>the FASB issued Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">606,</div> which provides comprehensive guidance for revenue recognition. Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">606</div> affects any entity which either enters into contracts with customers to transfer goods or services or enters into contracts for the transfer of nonfinancial assets. The core principle of the guidance provides that a company should recognize revenue when promised goods or services are transferred to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. Additionally, qualitative and quantitative disclosures are required about customer contracts, significant judgments and changes in judgments, and assets recognized from the costs to obtain or fulfill a contract. The new standard can be applied retrospectively to each prior reporting period presented or retrospectively with the cumulative effect of the change recognized at the date of the initial application in retained earnings. </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"> </div> <div style=" font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 54pt; text-align: justify;">On <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018,</div> we adopted Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">606</div> using the cumulative effect adoption method. Results for reporting periods beginning after <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018</div> are presented under Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">606,</div> while prior period amounts are <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> adjusted and continue to be reported in accordance with our historic accounting under Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">605.</div> We recorded a net reduction to opening accumulated deficit of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$76,000</div> as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018</div> due to the cumulative impact of adopting Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">606,</div> with the impact related to our collaboration revenues.</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 54pt; text-align: justify;">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 2016, </div>the FASB issued ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No.</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">01</div> (ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">01</div>), Recognition and Measurement of Financial Assets and Financial Liabilities. ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">01</div> changes accounting for equity investments, financial liabilities under the fair value option and the presentation and disclosure requirements for financial instruments. In addition, the update clarifies guidance related to the valuation allowance assessment when recognizing deferred tax assets resulting from unrealized losses on available-for-sale debt securities. We adopted ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">01</div> on <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 1, 2018 </div>and the adoption did <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> have a material impact on our financial statements.</div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"> </div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 54pt; text-align: justify;">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> May 2017, </div>the FASB issued ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No.</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">09</div> Compensation – Stock Compensation (Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">718</div>) Scope of Modification Accounting (ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">09</div>). The amendments in ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">09</div> provide guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">718.</div> We adopted ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">09</div> effective <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 1, 2018, </div>and the adoption did <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> have a material impact on our financial statements.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:58.5pt;margin-right:0pt;margin-top:0pt;text-align:left;"> </div> <table style="; text-indent: 0px; min-width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr style="vertical-align: top;"> <td style="width: 36pt;"> </td> <td style="width: 18pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">(</div></div><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">g</div></div><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">)</div></div></div> </td> <td> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Recently Issued Accounting Pronouncements</div></div></div> </td> </tr> </table> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:20.25pt;margin-right:0pt;margin-top:0pt;text-align:left;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:justify;">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> February 2016, </div>the FASB issued ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No.</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">02</div> Leases (Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">842</div>) (ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">02</div>), which supersedes existing guidance on accounting for leases in Leases (Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">840</div>) and generally requires all leases to be recognized in the consolidated balance sheet. ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">02</div> is effective for annual and interim reporting periods beginning after <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December 15, 2018; </div>early adoption is permitted. We do <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> plan to elect early adoption. The provisions of ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">02</div> are to be applied using a modified retrospective approach, or if we elect we <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> may </div>use a cumulative-effect adjustment to retained earnings as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2019.</div> We are currently assessing the future impact of this ASU on our consolidated financial statements.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:justify;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:justify;">In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June 2018, </div>the FASB issued ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">07</div> Compensation – Stock Compensation (Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">718</div>): Improvements to Nonemployee Share-Based Payment Accounting, (ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">07</div>). ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">07</div> expands the scope of Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">718</div> to include share-based payment transactions for acquiring goods and services from nonemployees. The guidance is intended to align the accounting for such payments to nonemployees with the existing requirements for share-based payments granted to employees. ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">07</div> is effective for fiscal years beginning after <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">15,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018</div> and is to be adopted through a cumulative-effect adjustment to retained earnings as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2019</div> for then outstanding share-based payments to nonemployees. We are currently assessing the future impact of this ASU on our consolidated financial statements.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"> </div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:54pt;margin-right:0pt;margin-top:0pt;text-align:justify;">Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, and the American Institute of Certified Public Accountants did <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> or are <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> believed by management to have a material impact on the Company’s financial statement presentation or disclosures.</div></div></div>

35000

23000

71000

22000

-3252000

-2968000

-6872000

-5843000

54000

-1000

35000

23000

71000

23000

46000

100000

1796000

0.001

25000000

282000

340000

5000

22000

114000

106000

471000

447000

55000

48000

326000

966000

927000

164000

169000

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="margin-right: 10%; margin-left: 27pt; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td colspan="1" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 66%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">June 30,<br /> 2018</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31,<br /> 2017</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 66%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Computer equipment and software</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">114</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">106</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 66%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Laboratory and manufacturing equipment</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">471</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">447</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 66%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Furniture and fixtures</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">55</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">48</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 66%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Leasehold improvements</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">326</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">326</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 66%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 18pt; text-align: left;">Property and equipment, gross</div> </td> <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">966</div></td> <td nowrap="nowrap" style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; border-bottom: 1px rgb(0, 0, 0); text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">927</div></td> <td nowrap="nowrap" style="width: 1%; border-bottom: 1px rgb(0, 0, 0); font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 66%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Less accumulated depreciation</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(802</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(758</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 66%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 18pt; text-align: left;">Property and equipment, net</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">164</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">169</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </table></div>

2031000

1295000

3986000

2328000

-79175000

-76000

-72450000

89000

101000

171000

210000

150000

11000

267000

39000

239000

112000

438000

249000

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="margin-right: 5%; margin-left: 27pt; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td colspan="1" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">June 30,</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td colspan="1" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2018</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2017</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 68%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Stock options to purchase common stock</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,678,200</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,008,634</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 68%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Unvested restricted stock units</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">40,888</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">98,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 68%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Total</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,719,088</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 13%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,106,634</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </table></div>

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="margin-right: 10%; margin-left: 27pt; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td colspan="1" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 44%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="14" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">As of June 30, 2018</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td colspan="1" style="width: 44%;"> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="vertical-align: bottom;"> <td colspan="1" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 44%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Level 1</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Level 2</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Level 3</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Total</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 44%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Assets:</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 44%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">Cash equivalents</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6,383</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">—</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">—</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6,383</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </table></div><div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="margin-right: 10%; margin-left: 27pt; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td colspan="1" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 44%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="14" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">As of December 31, 2017</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td colspan="1" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 44%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Level 1</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Level 2</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Level 3</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Total</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 44%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Assets:</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 44%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 9pt; text-align: left;">Cash equivalents</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12,063</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">—</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">—</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 11%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12,063</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </table></div>

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="margin-right: 20%; margin-left: 27pt; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td colspan="1" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 62%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">June 30,<br /> 2018</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31, </div></div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2017</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 62%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Raw materials</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">63</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">70</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 62%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Work in process</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">29</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">92</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 62%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Finished goods</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">44</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">29</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 62%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Total</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">136</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">191</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </table></div>

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="margin-right: 10%; margin-left: 27pt; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td colspan="1" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 66%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Weighted</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td colspan="1" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 66%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">average</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td colspan="1" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 66%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Number of</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">exercise</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> </tr> <tr style="vertical-align: bottom;"> <td colspan="1" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 66%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">shares</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">price</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 66%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Balance, December 31, 2017</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,213,100</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.96</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 66%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Stock options granted</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,603,075</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.48</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 66%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Stock options exercised</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(2,488</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.80</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 66%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Stock options cancelled</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(135,487</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.69</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 66%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Balance, June 30, 2018</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,678,200</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.83</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </table></div>

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="margin-right: 15%; margin-left: 27pt; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 81%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Risk-free interest rate</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 6%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: right;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.66%</div></td> <td style="width: 4%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 6%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.87%</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 81%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Volatility</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 6%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="width: 4%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">81%</div></td> <td style="width: 6%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 81%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Dividend yield</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"> </div> </td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 6%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 4%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">None</div></td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 6%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 81%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Expected term (in years)</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 6%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="width: 4%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6.25</div></td> <td style="width: 6%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </table></div>

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="margin-right: 15%; margin-left: 27pt; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 81%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Risk-free interest rate</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 6%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: right;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.80%</div></td> <td style="width: 4%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 6%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.84%</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 81%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Volatility</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 6%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: right;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">78%</div></td> <td style="width: 4%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 6%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">80%</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="1" style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 81%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Dividend yield</div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"> </div> </td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 6%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 4%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">None</div></td> <td style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 6%;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td colspan="1" style="text-align: left; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 81%;"> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Expected term (in years)</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 6%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: right;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8.1</div></td> <td style="width: 4%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: center;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 6%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8.8</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </table></div>

1325000

1582000

3032000

3386000

1353000

1298000

P4Y

97996

40888

8.71

11.04

57108

7.03

0.81

0.78

0.8

0.0266

0.0287

0.028

0.0284

135487

1603075

418977

1.77

4213100

5678200

1.80

2.96

2.83

1.80

2.69

2.48

P6Y91D

P8Y36D

P8Y292D

2488

5758000

11125000

38247288

38140232

38242728

38139063

xbrli:shares xbrli:pure iso4217:USD iso4217:USD xbrli:shares 0000925741 bcda:ConsultingServicesMember bcda:OPKOMember 2016-08-01 2016-08-31 0000925741 2017-01-01 2017-06-30 0000925741 us-gaap:EmployeeStockOptionMember 2017-01-01 2017-06-30 0000925741 us-gaap:RestrictedStockUnitsRSUMember 2017-01-01 2017-06-30 0000925741 bcda:CostOfGoodsSoldMember 2017-01-01 2017-06-30 0000925741 us-gaap:ResearchAndDevelopmentExpenseMember 2017-01-01 2017-06-30 0000925741 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2017-01-01 2017-06-30 0000925741 bcda:CollaborationAgreementMember 2017-01-01 2017-06-30 0000925741 us-gaap:ProductMember 2017-01-01 2017-06-30 0000925741 bcda:ConsultingServicesMember bcda:OPKOMember 2017-01-01 2017-06-30 0000925741 bcda:NonEmployeesMember 2017-01-01 2017-06-30 0000925741 2017-01-01 2017-12-31 0000925741 2017-04-01 2017-06-30 0000925741 bcda:CostOfGoodsSoldMember 2017-04-01 2017-06-30 0000925741 us-gaap:ResearchAndDevelopmentExpenseMember 2017-04-01 2017-06-30 0000925741 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2017-04-01 2017-06-30 0000925741 bcda:CollaborationAgreementMember 2017-04-01 2017-06-30 0000925741 us-gaap:ProductMember 2017-04-01 2017-06-30 0000925741 bcda:NonEmployeesMember 2017-04-01 2017-06-30 0000925741 2018-01-01 2018-06-30 0000925741 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-06-30 0000925741 us-gaap:RestrictedStockUnitsRSUMember 2018-01-01 2018-06-30 0000925741 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-06-30 0000925741 us-gaap:EmployeeStockOptionMember srt:MaximumMember 2018-01-01 2018-06-30 0000925741 us-gaap:EmployeeStockOptionMember srt:MinimumMember 2018-01-01 2018-06-30 0000925741 bcda:NonemployeeStockOptionsMember 2018-01-01 2018-06-30 0000925741 bcda:NonemployeeStockOptionsMember srt:MaximumMember 2018-01-01 2018-06-30 0000925741 bcda:NonemployeeStockOptionsMember srt:MinimumMember 2018-01-01 2018-06-30 0000925741 us-gaap:RestrictedStockUnitsRSUMember 2018-01-01 2018-06-30 0000925741 bcda:CostOfGoodsSoldMember 2018-01-01 2018-06-30 0000925741 us-gaap:ResearchAndDevelopmentExpenseMember 2018-01-01 2018-06-30 0000925741 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2018-01-01 2018-06-30 0000925741 bcda:CollaborationAgreementMember 2018-01-01 2018-06-30 0000925741 us-gaap:ProductMember 2018-01-01 2018-06-30 0000925741 bcda:ConsultingServicesMember bcda:OPKOMember 2018-01-01 2018-06-30 0000925741 bcda:ConsultantsMember 2018-01-01 2018-06-30 0000925741 bcda:NonEmployeesMember 2018-01-01 2018-06-30 0000925741 us-gaap:ScenarioForecastMember 2018-01-01 2018-12-31 0000925741 2018-04-01 2018-06-30 0000925741 bcda:CostOfGoodsSoldMember 2018-04-01 2018-06-30 0000925741 us-gaap:ResearchAndDevelopmentExpenseMember 2018-04-01 2018-06-30 0000925741 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2018-04-01 2018-06-30 0000925741 bcda:CollaborationAgreementMember 2018-04-01 2018-06-30 0000925741 us-gaap:ProductMember 2018-04-01 2018-06-30 0000925741 bcda:NonEmployeesMember 2018-04-01 2018-06-30 0000925741 bcda:ConsultingServicesMember bcda:OPKOMember 2016-08-31 0000925741 bcda:ChairmanAndChiefExecutiveOfficerOfOPKOMember 2016-08-31 0000925741 bcda:OPKOMember 2016-08-31 0000925741 2016-12-31 0000925741 2017-06-30 0000925741 2017-12-31 0000925741 us-gaap:RestrictedStockUnitsRSUMember 2017-12-31 0000925741 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000925741 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000925741 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000925741 us-gaap:FairValueMeasurementsRecurringMember 2017-12-31 0000925741 bcda:ComputerEquipmentAndSoftwareMember 2017-12-31 0000925741 us-gaap:FurnitureAndFixturesMember 2017-12-31 0000925741 bcda:LaboratoryAndManufacturingEquipmentMember 2017-12-31 0000925741 us-gaap:LeaseholdImprovementsMember 2017-12-31 0000925741 us-gaap:AccountingStandardsUpdate201409Member 2018-01-01 0000925741 2018-06-30 0000925741 us-gaap:RestrictedStockUnitsRSUMember 2018-06-30 0000925741 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-06-30 0000925741 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-06-30 0000925741 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-06-30 0000925741 us-gaap:FairValueMeasurementsRecurringMember 2018-06-30 0000925741 bcda:ComputerEquipmentAndSoftwareMember 2018-06-30 0000925741 us-gaap:FurnitureAndFixturesMember 2018-06-30 0000925741 bcda:LaboratoryAndManufacturingEquipmentMember 2018-06-30 0000925741 us-gaap:LeaseholdImprovementsMember 2018-06-30 0000925741 bcda:ConsultingServicesMember bcda:OPKOMember 2018-06-30 0000925741 2018-08-09

EX-101.SCH 7 bcda-20180630.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink 001 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) link:calculationLink link:definitionLink link:presentationLink 002 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 003 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:calculationLink link:definitionLink link:presentationLink 004 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:calculationLink link:definitionLink link:presentationLink 005 - Disclosure - Note 1 - Summary of Business and Basis of Presentation link:calculationLink link:definitionLink link:presentationLink 006 - Disclosure - Note 2 - Significant Accounting Policies link:calculationLink link:definitionLink link:presentationLink 007 - Disclosure - Note 3 - Fair Value Measurement link:calculationLink link:definitionLink link:presentationLink 008 - Disclosure - Note 4 - Inventories link:calculationLink link:definitionLink link:presentationLink 009 - Disclosure - Note 5 - Property and Equipment, Net link:calculationLink link:definitionLink link:presentationLink 010 - Disclosure - Note 6 - Accrued Expenses and Other Current Liabilities link:calculationLink link:definitionLink link:presentationLink 011 - Disclosure - Note 7 - Share-based Compensation link:calculationLink link:definitionLink link:presentationLink 013 - Disclosure - Note 9 - Income Taxes link:calculationLink link:definitionLink link:presentationLink 015 - Disclosure - Significant Accounting Policies (Policies) link:calculationLink link:definitionLink link:presentationLink 016 - Disclosure - Note 3 - Fair Value Measurement (Tables) link:calculationLink link:definitionLink link:presentationLink 017 - Disclosure - Note 4 - Inventories (Tables) link:calculationLink link:definitionLink link:presentationLink 018 - Disclosure - Note 5 - Property and Equipment, Net (Tables) link:calculationLink link:definitionLink link:presentationLink 019 - Disclosure - Note 6 - Accrued Expenses and Other Current Liabilities (Tables) link:calculationLink link:definitionLink link:presentationLink 020 - Disclosure - Note 7 - Share-based Compensation (Tables) link:calculationLink link:definitionLink link:presentationLink 022 - Disclosure - Note 2 - Significant Accounting Policies (Details Textual) link:calculationLink link:definitionLink link:presentationLink 023 - Disclosure - Note 3 - Fair Value Measurement - Fair Value of Assets Measured on a Recurring Basis (Details) link:calculationLink link:definitionLink link:presentationLink 024 - Disclosure - Note 4 - Inventories (Details Textual) link:calculationLink link:definitionLink link:presentationLink 025 - Disclosure - Note 4 - Inventories - Summary of Inventories (Details) link:calculationLink link:definitionLink link:presentationLink 026 - Disclosure - Note 5 - Property and Equipment, Net - Summary of Property and Equipment, Net (Details) link:calculationLink link:definitionLink link:presentationLink 027 - Disclosure - Note 6 - Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Details) link:calculationLink link:definitionLink link:presentationLink 028 - Disclosure - Note 7 - Share-based Compensation (Details Textual) link:calculationLink link:definitionLink link:presentationLink 029 - Disclosure - Note 7 - Share-based Compensation - Share-based Compensation Expense (Details) link:calculationLink link:definitionLink link:presentationLink 030 - Disclosure - Note 7 - Share-based Compensation - Stock Option Activity (Details) link:calculationLink link:definitionLink link:presentationLink 031 - Disclosure - Note 7 - Share-based Compensation - Valuation Assumptions for Employee Stock Options (Details) link:calculationLink link:definitionLink link:presentationLink 032 - Disclosure - Note 7 - Share-based Compensation - Summary of Non-vested RSUs (Details) link:calculationLink link:definitionLink link:presentationLink 033 - Disclosure - Note 7 - Share-based Compensation - Nonemployee Stock Option Valuation Assumptions (Details) link:calculationLink link:definitionLink link:presentationLink 035 - Disclosure - Note 9 - Income Taxes (Details Textual) link:calculationLink link:definitionLink link:presentationLink EX-101.CAL 8 bcda-20180630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 bcda-20180630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 bcda-20180630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document And Entity Information Dividend yield Dividend yield Note To Financial Statement Details Textual Significant Accounting Policies Note 3 - Fair Value Measurement Note 4 - Inventories Risk-free interest rate Risk-free interest rate Note 5 - Property and Equipment, Net Note 6 - Accrued Expenses and Other Current Liabilities Note 7 - Share-based Compensation Note 8 - Net Loss Per Share Note 3 - Fair Value Measurement - Fair Value of Assets Measured on a Recurring Basis (Details) Note 4 - Inventories - Summary of Inventories (Details) Income Tax Disclosure [Text Block] Note 5 - Property and Equipment, Net - Summary of Property and Equipment, Net (Details) Note 6 - Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Details) Note 7 - Share-based Compensation - Share-based Compensation Expense (Details) Volatility Volatility Share-based compensation Other assets Note 7 - Share-based Compensation - Stock Option Activity (Details) Note 7 - Share-based Compensation - Valuation Assumptions for Employee Stock Options (Details) us-gaap_LiabilitiesCurrent Total current liabilities Note 7 - Share-based Compensation - Summary of Non-vested RSUs (Details) Title of Individual [Axis] Note 7 - Share-based Compensation - Nonemployee Stock Option Valuation Assumptions (Details) Relationship to Entity [Domain] Note 8 - Net Loss Per Share - Anti-dilutive Securities (Details) Expected term (in years) (Year) Notes To Financial Statements Notes To Financial Statements [Abstract] Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Share-based Compensation, Stock Options, Activity [Table Text Block] RSUs vested, Weighted average grant date fair value per share (in dollars per share) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue Balance, Weighted average grant date fair value per share (in dollars per share) Balance, Weighted average grant date fair value per share (in dollars per share) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber Balance, Shares (in shares) Balance, Shares (in shares) Depreciation and amortization us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod RSUs vested, Shares (in shares) Collaboration Agreement [Member] Represents the information pertaining to the collaboration agreement. Schedule of Nonvested Restricted Stock Units Activity [Table Text Block] Assets: us-gaap_AssetsCurrent Total current assets us-gaap_CashAndCashEquivalentsFairValueDisclosure Cash equivalents us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value us-gaap_PaymentsToAcquireShortTermInvestments Purchase of short-term investments Common stock, $0.001 par value, 100,000,000 shares authorized as of June 30, 2018 and December 31, 2017 respectively; 38,277,908 and 38,218,660 shares issued and outstanding as of June 30, 2018 and December 31, 2017, respectively Adjustments to reconcile net loss to net cash used in operating activities: Measurement Frequency [Axis] us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance Balance, weighted average exercise price, beginning of period (in dollars per share) Balance, weighted average exercise price, end of period (in dollars per share) Fair Value, Measurement Frequency [Domain] Fair Value, Measurements, Recurring [Member] Common stock, shares authorized (in shares) Stock options cancelled, weighted average exercise price (in dollars per share) Common stock, shares issued (in shares) Common stock, par value (in dollars per share) Stock options granted, weighted average exercise price (in dollars per share) Revenue from Contract with Customer [Policy Text Block] Stock options exercised, weighted average exercise price (in dollars per share) Accrued expenses Accrued employee costs Range [Domain] Maximum [Member] Minimum [Member] Accounts payable Product and Service [Axis] us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Stock options outstanding, beginning of period (in shares) Stock options outstanding, end of period (in shares) Product and Service [Domain] Range [Axis] bcda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedGrantDateFairValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Grant Date Fair Value Grant-date fair value of non-vested options outstanding. Preferred stock, $0.001 par value, 25,000,000 shares authorized; no shares issued and outstanding as of June 30, 2018 and December 31, 2017 Preferred stock, shares issued (in shares) us-gaap_PolicyTextBlockAbstract Accounting Policies Prepaid expenses Property, Plant and Equipment Disclosure [Text Block] Property, Plant and Equipment [Table Text Block] Preferred stock, shares authorized (in shares) Inventory Total Preferred stock, par value (in dollars per share) Total revenue Fair Value, Inputs, Level 3 [Member] us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Purchase of property and equipment Fair Value Hierarchy and NAV [Domain] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 2 [Member] us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Fair Value Hierarchy and NAV [Axis] Current liabilities: Product [Member] us-gaap_Assets Total assets Deferred revenue us-gaap_IncreaseDecreaseInDeferredRevenue us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options Operating activities: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition Statement [Line Items] Allowance for doubtful accounts Furniture and Fixtures [Member] Accounts receivable, net of allowance for doubtful accounts of $3 and $6 at June 30, 2018 and December 31, 2017, respectively Additional paid-in capital us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount Employee Service Share-based Compensation, Allocation of Recognized Period Costs, Capitalized Amount Revenue: Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Stockholders’ equity: Leasehold Improvements [Member] Other expense, net Property, Plant and Equipment, Type [Axis] us-gaap_NonoperatingIncomeExpense Total other income, net Property, Plant and Equipment, Type [Domain] Business Description and Basis of Presentation [Text Block] Equity Award [Domain] Customer deposits Current assets: Fair Value Disclosures [Text Block] Award Type [Axis] Net loss Net loss Restricted Stock Units (RSUs) [Member] us-gaap_NetCashProvidedByUsedInFinancingActivities Net cash provided by financing activities us-gaap_Liabilities Total liabilities Interest income us-gaap_OperatingIncomeLoss Operating loss Employee Stock Option [Member] Other income (expense): us-gaap_NetCashProvidedByUsedInOperatingActivities Net cash used in operating activities us-gaap_DeferredTaxLiabilities Deferred Tax Liabilities, Net, Total us-gaap_NetCashProvidedByUsedInInvestingActivities Net used in in investing activities Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Accrued expenses and other current liabilities Total Amount of accrued liabilities and liabilities classified as other, due within one year or the normal operating cycle, if longer. Cost of goods sold us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect Net decrease in cash and cash equivalents Accounting Standards Update 2014-09 [Member] us-gaap_InventoryWriteDown Inventory Write-down us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Less accumulated depreciation Property and equipment, net Property and equipment, net Schedule of Accrued Liabilities and Other Current Liabilities [Table Text Block] Tabular disclosure of the components of accrued liabilities and other current liabilities. Accrued Liabilities and Other Current Liabilities Disclosure [Text Block] The entire disclosure for accrued liabilities and other current liabilities at the end of the reporting period. Grant liability Amount of obligations incurred for grants, payable within one year or the normal operating cycle, if longer. Property and equipment, gross Type of Adoption [Domain] Adjustments for New Accounting Pronouncements [Axis] us-gaap_CostsAndExpenses Total costs and expenses Costs and expenses: Investing activities: Earnings Per Share [Text Block] Proceeds from the exercise of common stock options Related Party Transactions Disclosure [Text Block] us-gaap_IncomeTaxExpenseBenefit Income Tax Expense (Benefit), Total Accrued liabilities Equity Components [Axis] Equity Component [Domain] Accounts payable us-gaap_IncreaseDecreaseInAccountsPayable Deferred revenue Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value, Ending Balance Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Share-based compensation expense us-gaap_AllocatedShareBasedCompensationExpense Allocated Share-based Compensation Expense, Total Deferred rent us-gaap_IncreaseDecreaseInDeferredLiabilities Amendment Flag Accounting Policies [Abstract] Significant Accounting Policies [Text Block] Basis of Accounting, Policy [Policy Text Block] Use of Estimates, Policy [Policy Text Block] New Accounting Pronouncements, Policy [Policy Text Block] Selling, General and Administrative Expenses [Member] Going Concern and Liquidity [Policy Text Block] Disclosure of accounting policy for reporting when there is, or is not, a substantial doubt about an entity's ability to continue as a going concern for a reasonable period of time (generally a year from the balance sheet date). Disclose: (a) pertinent conditions and events giving rise to the assessment of substantial doubt about the entity's ability to continue as a going concern for a reasonable period of time, (b) the possible effects of such conditions and events, (c) management's evaluation of the significance of those conditions and events and any mitigating factors, (d) possible discontinuance of operations, (e) management's plans (including relevant prospective financial information), and (f) information about the recoverability or classification of recorded asset amounts or the amounts or classification of liabilities. If management's plans alleviate the substantial doubt about the entity's ability to continue as a going concern, disclosure of the principal conditions and events that initially raised the substantial doubt about the entity's ability to continue as a going concern would be expected to be considered. Disclose whether operations for the current or prior years generated sufficient cash to cover current obligations, whether waivers were obtained from creditors relating to the company's default under the provisions of debt agreements and possible effects of such conditions and events, such as: whether there is a possible need to obtain additional financing (debt or equity) or to liquidate certain holdings to offset future cash flow deficiencies. Disclose appropriate parent company information when parent is dependent upon remittances from subsidiaries to satisfy its obligations. Common stock, shares outstanding (in shares) Preferred stock, shares outstanding (in shares) Current Fiscal Year End Date Cost of Goods Sold [Member] Related to the cost of goods sold. us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Prepaid expenses Computer Equipment and Software [Member] Related to computer equipment and software. Research and Development Expense [Member] Document Fiscal Period Focus Document Fiscal Year Focus Consolidation, Policy [Policy Text Block] Laboratory and Manufacturing Equipment [Member] Related to laboratory and manufacturing equipment. Document Period End Date Income Statement Location [Axis] Income Statement Location [Domain] Document Type Document Information [Line Items] Document Information [Table] Entity Filer Category Entity Current Reporting Status Entity Voluntary Filers Entity Well-known Seasoned Issuer Consultants [Member] Represents information pertaining to consultants. Schedule of Share-based Compensation, Expense [Table Text Block] Tabular disclosure of the components of the allocated share-based compensation expense. Non-employees [Member] Represents information pertaining to non-employees. Non-employee Stock Options [Member] Related to non-employee stock options. Weighted-average shares used in computing net loss per share, basic and diluted (in shares) Antidilutive securities (in shares) EX-101.PRE 11 bcda-20180630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 12 R1.htm IDEA: XBRL DOCUMENT

Document And Entity Information - shares	6 Months Ended
Document And Entity Information - shares	Jun. 30, 2018	Aug. 09, 2018
Document Information [Line Items]
Entity Registrant Name	BioCardia, Inc.
Entity Central Index Key	0000925741
Trading Symbol	bcda
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding (in shares)		38,277,908
Document Type	10-Q
Document Period End Date	Jun. 30, 2018
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	Q2
Amendment Flag	false

XML 13 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 6,834	$ 12,689
Accounts receivable, net of allowance for doubtful accounts of $3 and $6 at June 30, 2018 and December 31, 2017, respectively	191	95
Inventory	136	191
Prepaid expenses	282	340
Total current assets	7,443	13,315
Property and equipment, net	164	169
Other assets	54	54
Total assets	7,661	13,538
Current liabilities:
Accounts payable	505	902
Accrued expenses and other current liabilities	1,314	1,263
Deferred revenue		167
Total current liabilities	1,819	2,332
Deferred rent	84	81
Total liabilities	1,903	2,413
Stockholders’ equity:
Preferred stock, $0.001 par value, 25,000,000 shares authorized; no shares issued and outstanding as of June 30, 2018 and December 31, 2017
Common stock, $0.001 par value, 100,000,000 shares authorized as of June 30, 2018 and December 31, 2017 respectively; 38,277,908 and 38,218,660 shares issued and outstanding as of June 30, 2018 and December 31, 2017, respectively	38	38
Additional paid-in capital	84,895	83,537
Accumulated deficit	(79,175)	(72,450)
Total stockholders’ equity	5,758	11,125
Total liabilities and stockholders’ equity	$ 7,661	$ 13,538

XML 14 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Allowance for doubtful accounts	$ 3	$ 6
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	25,000,000	25,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	100,000,000	100,000,000
Common stock, shares issued (in shares)	38,277,908	38,218,660
Common stock, shares outstanding (in shares)	38,277,908	38,218,660

XML 15 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Revenue:
Total revenue	$ 239	$ 112	$ 438	$ 249
Costs and expenses:
Cost of goods sold	135	203	292	378
Research and development	2,031	1,295	3,986	2,328
Selling, general and administrative	1,325	1,582	3,032	3,386
Total costs and expenses	3,491	3,080	7,310	6,092
Operating loss	(3,252)	(2,968)	(6,872)	(5,843)
Other income (expense):
Interest income	35	23	71	23
Other expense, net				(1)
Total other income, net	35	23	71	22
Net loss	$ (3,217)	$ (2,945)	$ (6,801)	$ (5,821)
Net loss per share, basic and diluted (in dollars per share)	$ (0.08)	$ (0.08)	$ (0.18)	$ (0.15)
Weighted-average shares used in computing net loss per share, basic and diluted (in shares)	38,247,288	38,140,232	38,242,728	38,139,063
Product [Member]
Revenue:
Total revenue	$ 89	$ 101	$ 171	$ 210
Collaboration Agreement [Member]
Revenue:
Total revenue	$ 150	$ 11	$ 267	$ 39

XML 16 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Operating activities:
Net loss	$ (6,801)	$ (5,821)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	44	36
Share-based compensation	1,353	1,298
Changes in operating assets and liabilities:
Accounts receivable	(96)	(68)
Inventory	55	(58)
Prepaid expenses	58	74
Accounts payable	(390)	60
Accrued liabilities	25	16
Deferred revenue	(65)	82
Deferred rent	3	12
Net cash used in operating activities	(5,814)	(4,369)
Investing activities:
Purchase of property and equipment	(46)	(100)
Purchase of short-term investments		(1,796)
Net used in in investing activities	(46)	(1,896)
Financing activities:
Proceeds from the exercise of common stock options	5	22
Net cash provided by financing activities	5	22
Net decrease in cash and cash equivalents	(5,855)	(6,243)
Cash and cash equivalents at beginning of period	12,689	21,352
Cash and cash equivalents at end of period	$ 6,834	$ 15,109

XML 17 R6.htm IDEA: XBRL DOCUMENT

Note 1 - Summary of Business and Basis of Presentation

6 Months Ended

Jun. 30, 2018

Notes to Financial Statements

Business Description and Basis of Presentation [Text Block]

(

)

Summary of Business and Basis of Presentation

Description of Business

two

large cardiac indications under FDA approved pivotal trials. Our

second

therapeutic candidate is the CardiALLO Cell Therapy System, an investigational allogenic culture expanded “off the shelf” mesenchymal cell therapy being advanced initially to treat patients who are

not

eligible for CardiAMP cell therapy due to the quality of their cells. To date, we have devoted substantially all our resources to research and development efforts relating to our therapeutic candidates and biotherapeutic delivery systems including conducting clinical trials, developing manufacturing and sales capabilities, in-licensing related intellectual property, providing general and administrative support for these operations and protecting our intellectual property.

We have

three

enabling device product lines which have

one

or more approvals in the USA and/or EU: (

) the CardiAMP cell processing system; (

) the Helix biotherapeutic delivery system, or Helix; and (

) the Morph vascular access product line, or Morph. We manage our operations as a single segment for the purposes of assessing performance and making operating decisions.

XML 18 R7.htm IDEA: XBRL DOCUMENT

Note 2 - Significant Accounting Policies

6 Months Ended

Jun. 30, 2018

Notes to Financial Statements

Significant Accounting Policies [Text Block]

(

)

Significant Accounting Policies

(a)

Basis of Preparation

The accompanying condensed consolidated balance sheets, statements of operations and cash flows as of and for the

three

and

six

months ended

June 30, 2018

and

2017

are unaudited. The condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America, or U.S. GAAP, and applicable rules and regulations of the Securities and Exchange Commission, or SEC, for interim financial information and on a basis consistent with the annual financial statements. In the opinion of management, they also reflect all adjustments which include only normal recurring adjustments, necessary to present fairly our financial position for the interim periods presented. The results for the

three

and

six

months ended

June 30, 2018

are

not

necessarily indicative of the results to be expected for the year ending

December 31, 2018

or for any other interim period or for any other future year.

These condensed consolidated financial statements should be read in conjunction with the audited financial statements and related notes included in our Annual Report on Form

-K for the year ended

December 31, 2017,

filed with the SEC on

March 16, 2018.

(b)

Liquidity

We have incurred net losses and negative cash flows from operations since our inception and had an accumulated deficit of

$79.2

million as of

June 30, 2018.

Management expects operating losses and negative cash flows to continue through the next several years. Based on management’s current plans, management believes cash and cash equivalents of

$6.8

million as of

June 30, 2018

are sufficient to fund us into

December 2018.

These factors raise substantial doubt about our ability to continue as a going concern beyond

one

year from the date these financial statements are issued. The financial statements do

not

include any adjustments that might result from the outcome of this uncertainty.

Our ability to continue as a going concern and to continue further development of our lead therapeutic candidate, the CardiAMP Cell Therapy System, and our

second

therapeutic candidate, the CardiALLO Cell Therapy System, through and beyond

December 2018,

will require us to raise additional capital. We plan to raise additional capital, potentially including debt and equity arrangements, to finance our future operations. If adequate funds are

not

available, we

may

be required to reduce operating expenses, delay or reduce the scope of our product development programs, obtain funds through arrangements with others that

may

require us to relinquish rights to certain of our technologies or products that we would otherwise seek to develop or commercialize ourselves, or cease operations. While we believe we have a viable strategy to raise additional funds, there can be

assurances that we will be able to obtain additional capital on acceptable terms and in the amounts necessary to fully fund our operating needs.

(c)

Use of Estimates

(d)

Principles of Consolidation

(e)

Changes to

Significant Accounting Policies

Our significant accounting policies are described in Note

of the notes to the financial statements included in our Annual Report on Form

-K filed for the year ended

December 31, 2017.

Apart from the adoption of ASU

No.

2014

09,

Revenue from Contracts with Customers (Topic

606

) on

January 1, 2018

which led to an amended revenue policy, as described in the following paragraphs, there have been

changes to those policies.

Revenue Recognition

Net product revenue

– We currently have a portfolio of enabling and delivery products. Revenue from product sales is recognized generally upon shipment to the end customer, which is when control of the product is deemed to be transferred.

Collaboration agreement revenue

– Collaboration agreement revenue is income from agreements under partnering programs with corporate and academic institutions, wherein we provide biotherapeutic delivery systems and customer training and support for their use in clinical trials and studies. These programs provide additional clinical data, intellectual property rights and opportunities to participate in the development of combination products for the treatment of cardiac disease.

Amounts received from customers in advance of revenue recognition are recorded as deferred revenue on the consolidated balance sheets.

(

)

Recently Adopted Accounting Pronouncement

May 2014,

the FASB issued Topic

606,

which provides comprehensive guidance for revenue recognition. Topic

606

affects any entity which either enters into contracts with customers to transfer goods or services or enters into contracts for the transfer of nonfinancial assets. The core principle of the guidance provides that a company should recognize revenue when promised goods or services are transferred to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. Additionally, qualitative and quantitative disclosures are required about customer contracts, significant judgments and changes in judgments, and assets recognized from the costs to obtain or fulfill a contract. The new standard can be applied retrospectively to each prior reporting period presented or retrospectively with the cumulative effect of the change recognized at the date of the initial application in retained earnings.

January

2018,

we adopted Topic

606

using the cumulative effect adoption method. Results for reporting periods beginning after

January

2018

are presented under Topic

606,

while prior period amounts are

not

adjusted and continue to be reported in accordance with our historic accounting under Topic

605.

We recorded a net reduction to opening accumulated deficit of

$76,000

as of

January

2018

due to the cumulative impact of adopting Topic

606,

with the impact related to our collaboration revenues.

January 2016,

the FASB issued ASU

No.

2016

(ASU

2016

), Recognition and Measurement of Financial Assets and Financial Liabilities. ASU

2016

changes accounting for equity investments, financial liabilities under the fair value option and the presentation and disclosure requirements for financial instruments. In addition, the update clarifies guidance related to the valuation allowance assessment when recognizing deferred tax assets resulting from unrealized losses on available-for-sale debt securities. We adopted ASU

2016

January 1, 2018

and the adoption did

not

have a material impact on our financial statements.

May 2017,

the FASB issued ASU

No.

2017

Compensation – Stock Compensation (Topic

718

) Scope of Modification Accounting (ASU

2017

). The amendments in ASU

2017

provide guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic

718.

We adopted ASU

2017

effective

January 1, 2018,

and the adoption did

not

have a material impact on our financial statements.

(

)

Recently Issued Accounting Pronouncements

February 2016,

the FASB issued ASU

No.

2016

Leases (Topic

842

) (ASU

2016

), which supersedes existing guidance on accounting for leases in Leases (Topic

840

) and generally requires all leases to be recognized in the consolidated balance sheet. ASU

2016

is effective for annual and interim reporting periods beginning after

December 15, 2018;

early adoption is permitted. We do

not

plan to elect early adoption. The provisions of ASU

2016

are to be applied using a modified retrospective approach, or if we elect we

may

use a cumulative-effect adjustment to retained earnings as of

January

2019.

We are currently assessing the future impact of this ASU on our consolidated financial statements.

June 2018,

the FASB issued ASU

2018

Compensation – Stock Compensation (Topic

718

): Improvements to Nonemployee Share-Based Payment Accounting, (ASU

2018

). ASU

2018

expands the scope of Topic

718

to include share-based payment transactions for acquiring goods and services from nonemployees. The guidance is intended to align the accounting for such payments to nonemployees with the existing requirements for share-based payments granted to employees. ASU

2018

is effective for fiscal years beginning after

December

15,

2018

and is to be adopted through a cumulative-effect adjustment to retained earnings as of

January

2019

for then outstanding share-based payments to nonemployees. We are currently assessing the future impact of this ASU on our consolidated financial statements.

Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, and the American Institute of Certified Public Accountants did

not

or are

not

believed by management to have a material impact on the Company’s financial statement presentation or disclosures.

XML 19 R8.htm IDEA: XBRL DOCUMENT

Note 3 - Fair Value Measurement

6 Months Ended

Jun. 30, 2018

Notes to Financial Statements

Fair Value Disclosures [Text Block]

(

)

Fair Value Measurement

three

levels:

Level

– quoted prices in active markets for identical assets and liabilities

Level

– observable inputs other than quoted prices in active markets for identical assets and liabilities; quoted prices in markets that are

not

active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities

Level

– unobservable inputs that are supported by little or

market activity and that are significant to the fair value of the assets or liabilities.

The following table sets forth the fair value of our financial assets measured on a recurring basis as of

June 30, 2018

and

December 31, 2017

and indicates the fair value hierarchy utilized to determine such fair value (in thousands).

	As of June 30, 2018

	Level 1		Level 2		Level 3		Total
Assets:
Cash equivalents	$	6,383	$	—	$	—	$	6,383

	As of December 31, 2017
	Level 1		Level 2		Level 3		Total
Assets:
Cash equivalents	$	12,063	$	—	$	—	$	12,063

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

XML 20 R9.htm IDEA: XBRL DOCUMENT

Note 4 - Inventories

6 Months Ended

Jun. 30, 2018

Notes to Financial Statements

Inventory Disclosure [Text Block]

(

)

Inventories

Inventories are stated at the lower of cost or net realizable value using the average cost method. Inventories consisted of the following (in thousands):

	June 30, 2018		December 31, 2017
Raw materials	$	63	$	70
Work in process		29		92
Finished goods		44		29
Total	$	136	$	191

may

result in recording additional write downs for excess or expired inventory in the future. Charges to cost of goods sold for inventory write-downs, reserve adjustments, scrap, and expired inventories totaled approximately

$12,000

and

$1,000

for the

three

months ended

June 30, 2018

and

2017

respectively, and

$15,000

and

$10,000

for the

six

months ended

June 30, 2018

and

2017,

respectively.

XML 21 R10.htm IDEA: XBRL DOCUMENT

Note 5 - Property and Equipment, Net

6 Months Ended

Jun. 30, 2018

Notes to Financial Statements

Property, Plant and Equipment Disclosure [Text Block]

(

)

Property and Equipment, Net

Property and equipment, net consisted of the following (in thousands):

	June 30, 2018			December 31, 2017
Computer equipment and software	$	114		$	106
Laboratory and manufacturing equipment		471			447
Furniture and fixtures		55			48
Leasehold improvements		326			326
Property and equipment, gross		966			927
Less accumulated depreciation		(802	)		(758	)
Property and equipment, net	$	164		$	169

XML 22 R11.htm IDEA: XBRL DOCUMENT

Note 6 - Accrued Expenses and Other Current Liabilities

6 Months Ended

Jun. 30, 2018

Notes to Financial Statements

Accrued Liabilities and Other Current Liabilities Disclosure [Text Block]

(

)

Accrued

Expenses and Other Current

Liabilities

Accrued expenses and other current liabilities consisted of the following (in thousands):

	June 30, 2018		December 31, 2017
Accrued expenses	$	180	$	129
Accrued employee costs		412		410
Grant liability		635		663
Customer deposits		87		61
Total	$	1,314	$	1,263

XML 23 R12.htm IDEA: XBRL DOCUMENT

Note 7 - Share-based Compensation

6 Months Ended

Jun. 30, 2018

Notes to Financial Statements

Disclosure of Compensation Related Costs, Share-based Payments [Text Block]

(

)

Share-Based Compensation

The share-based compensation expense is recorded in cost of goods sold, research and development, and selling, general and administrative expenses based on the employee's respective function.

share-based compensation was capitalized during the periods presented. Share-based compensation expense for the

three

and

six

months ended

June 30, 2018

and

2017

was recorded as follows (in thousands):

	Three months ended June 30,				Six months ended June 30,
	2018		2017		2018		2017
Cost of goods sold	$	36	$	33	$	66	$	74
Research and development		264		154		461		326
Selling, general and administrative		438		489		826		898
Share-based compensation expense	$	738	$	676	$	1,353	$	1,298

The following table summarizes the activity of stock options and related information:

				Weighted
				average
	Number of			exercise
	shares			price
Balance, December 31, 2017		4,213,100		$	2.96
Stock options granted		1,603,075			2.48
Stock options exercised		(2,488	)		1.80
Stock options cancelled		(135,487	)		2.69
Balance, June 30, 2018		5,678,200		$	2.83

The weighted average grant-date fair value of options granted during the

six

months ended

June 30, 2018

was

$1.77

per share.

Employee Share-Based Compensation (Stock Options)

During the

six

months ended

June 30, 2018,

we granted stock options to certain non-employee directors and employees to purchase

1,603,075

shares of common stock. The fair value of each option grant was estimated on the date of the grant using the Black-Scholes option pricing model with the following assumptions:

Risk-free interest rate	2.66%	-	2.87%
Volatility		81%
Dividend yield		None
Expected term (in years)		6.25

Unrecognized share-based compensation for employee options as of

June 30, 2018

was approximately

$6.3

million to be recognized over a remaining weighted average service period of

2.8

years.

Restricted Stock Units

(RSUs)

The following summarizes the activity of non-vested RSUs:

				Weighted
				average
				grant date
	Number of			fair value
	shares			per share
Balance, December 31, 2017		97,996		$	8.71
RSUs vested		(57,108	)		7.03
Balance, June 30, 2018		40,888		$	11.04

Unrecognized share-based compensation for employee RSUs granted as of

June 30, 2018

was approximately

$348,000

to be recognized over a remaining weighted average service period of

1.5

years.

Nonemployee Share-Based Compensation

During the

six

months ended

June 30, 2018,

we did

not

grant any options to purchase shares of common stock to consultants. Options granted to consultants have been granted in exchange for consulting services to be rendered and vest over the term specified in the grant, which correlates to the period the services are rendered. We recorded

$31,000

and

$277,000

for the

three

months ended

June 30, 2018

and

2017,

respectively, and

$76,000

and

$510,000

for the

six

months ended

June 30, 2018

and

2017,

respectively as nonemployee share-based compensation expense.

six

months ended

June 30, 2018:

Risk-free interest rate	2.80%	-	2.84%
Volatility	78%	-	80%
Dividend yield		None
Expected term (in years)	8.1	-	8.8

XML 24 R13.htm IDEA: XBRL DOCUMENT

Note 8 - Net Loss Per Share

6 Months Ended

Jun. 30, 2018

Notes to Financial Statements

Earnings Per Share [Text Block]

(

)

Net Loss per Share

difference in the number of shares used to calculate basic and diluted shares outstanding since the effects of potentially dilutive securities are antidilutive due to our net loss position.

The following outstanding common stock equivalents were excluded from the computation of diluted net loss per share for the periods presented because including them would have been antidilutive:

	June 30,
	2018		2017
Stock options to purchase common stock		5,678,200		4,008,634
Unvested restricted stock units		40,888		98,000
Total		5,719,088		4,106,634

XML 25 R14.htm IDEA: XBRL DOCUMENT

Note 9 - Income Taxes

6 Months Ended

Jun. 30, 2018

Notes to Financial Statements

Income Tax Disclosure [Text Block]

(

)

Income Taxes

During the

six

months ended

June 30, 2018

and

2017,

there was

income tax expense or benefit for federal or state income taxes in the accompanying condensed consolidated statements of operations due to the Company’s net loss and a full valuation allowance on the resulting deferred tax assets.

As of

June 30, 2018,

we retain a full valuation allowance on our deferred tax assets in all jurisdictions. The realization of our deferred tax assets depends primarily on our ability to generate future taxable income which is uncertain. We do

not

believe that our deferred tax assets are realizable on a more-likely-than-

not

basis; therefore, the net deferred tax assets have been fully offset by a valuation allowance.

December 22, 2017,

the Tax Cuts and Jobs Act (H.R.

) (the Tax Act) was signed into law. The new law resulted in significant changes to the U.S. corporate income tax system. These changes included the reduction of the corporate income tax rate from a maximum rate of

35%

21%

and the elimination or reduction of certain domestic deductions and credits.

The

2017

provisional charge related to the Tax Act was an estimate and the measurement of net deferred tax assets is subject to further analysis and potential correlative adjustments as developing interpretations and guidance from the U.S. Treasury Department, the Internal Revenue Service, and other standard setting bodies provide additional clarifications of the provisions of the Tax Act. Updated guidance and regulations could result in changes to this provisional charge during

2018

when the analysis is complete, and, in accordance with the guidance in Staff Accounting Bulletin

118,

we will continue to monitor guidance and make necessary adjustments.

measurement-period adjustments were made during the

six

months ended

June 30, 2018.

XML 26 R15.htm IDEA: XBRL DOCUMENT

Note 10 - Related Party Transactions

6 Months Ended

Jun. 30, 2018

Notes to Financial Statements

(

)

Related Party Transactions

August 2016,

we granted an option to purchase

418,977

shares of common stock, with a

four

year vesting period and an exercise price of

$1.80

per share, to OPKO Health, Inc. (“OPKO”) as consideration for consulting services to be provided by OPKO. We recorded

$62,000

and

$306,000

as share-based compensation expense related to the OPKO stock option during the

six

months ended

June 30, 2018

and

2017,

respectively. The estimated grant-date fair value of the option was

$5.3

million. The term of the consulting agreement is

four

years and will be automatically renewed for successive

one

year periods. The chairman and chief executive officer of OPKO is a beneficial owner of more than

of the outstanding shares of our common stock and OPKO itself is also a beneficial owner of more than

of the outstanding shares of our common stock.

XML 27 R16.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies (Policies)

6 Months Ended

Jun. 30, 2018

Accounting Policies [Abstract]

Basis of Accounting, Policy [Policy Text Block]

(a)

Basis of Preparation

The accompanying condensed consolidated balance sheets, statements of operations and cash flows as of and for the

three

and

six

months ended

June 30, 2018

and

2017

three

and

six

months ended

June 30, 2018

are

not

necessarily indicative of the results to be expected for the year ending

December 31, 2018

or for any other interim period or for any other future year.

These condensed consolidated financial statements should be read in conjunction with the audited financial statements and related notes included in our Annual Report on Form

-K for the year ended

December 31, 2017,

filed with the SEC on

March 16, 2018.

Going Concern and Liquidity [Policy Text Block]

(b)

Liquidity

We have incurred net losses and negative cash flows from operations since our inception and had an accumulated deficit of

$79.2

million as of

June 30, 2018.

Management expects operating losses and negative cash flows to continue through the next several years. Based on management’s current plans, management believes cash and cash equivalents of

$6.8

million as of

June 30, 2018

are sufficient to fund us into

December 2018.

These factors raise substantial doubt about our ability to continue as a going concern beyond

one

year from the date these financial statements are issued. The financial statements do

not

include any adjustments that might result from the outcome of this uncertainty.

Our ability to continue as a going concern and to continue further development of our lead therapeutic candidate, the CardiAMP Cell Therapy System, and our

second

therapeutic candidate, the CardiALLO Cell Therapy System, through and beyond

December 2018,

will require us to raise additional capital. We plan to raise additional capital, potentially including debt and equity arrangements, to finance our future operations. If adequate funds are

not

available, we

may

be required to reduce operating expenses, delay or reduce the scope of our product development programs, obtain funds through arrangements with others that

may

assurances that we will be able to obtain additional capital on acceptable terms and in the amounts necessary to fully fund our operating needs.

Use of Estimates, Policy [Policy Text Block]

(c)

Use of Estimates

Consolidation, Policy [Policy Text Block]

(d)

Principles of Consolidation

Revenue from Contract with Customer [Policy Text Block]

(e)

Changes to

Significant Accounting Policies

Our significant accounting policies are described in Note

of the notes to the financial statements included in our Annual Report on Form

-K filed for the year ended

December 31, 2017.

Apart from the adoption of ASU

No.

2014

09,

Revenue from Contracts with Customers (Topic

606

) on

January 1, 2018

which led to an amended revenue policy, as described in the following paragraphs, there have been

changes to those policies.

Revenue Recognition

Net product revenue

Collaboration agreement revenue

Amounts received from customers in advance of revenue recognition are recorded as deferred revenue on the consolidated balance sheets.

New Accounting Pronouncements, Policy [Policy Text Block]

(

)

Recently Adopted Accounting Pronouncement

May 2014,

the FASB issued Topic

606,

which provides comprehensive guidance for revenue recognition. Topic

606

January

2018,

we adopted Topic

606

using the cumulative effect adoption method. Results for reporting periods beginning after

January

2018

are presented under Topic

606,

while prior period amounts are

not

adjusted and continue to be reported in accordance with our historic accounting under Topic

605.

We recorded a net reduction to opening accumulated deficit of

$76,000

as of

January

2018

due to the cumulative impact of adopting Topic

606,

with the impact related to our collaboration revenues.

January 2016,

the FASB issued ASU

No.

2016

(ASU

2016

), Recognition and Measurement of Financial Assets and Financial Liabilities. ASU

2016

January 1, 2018

and the adoption did

not

have a material impact on our financial statements.

May 2017,

the FASB issued ASU

No.

2017

Compensation – Stock Compensation (Topic

718

) Scope of Modification Accounting (ASU

2017

). The amendments in ASU

2017

provide guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic

718.

We adopted ASU

2017

effective

January 1, 2018,

and the adoption did

not

have a material impact on our financial statements.

(

)

Recently Issued Accounting Pronouncements

February 2016,

the FASB issued ASU

No.

2016

Leases (Topic

842

) (ASU

2016

), which supersedes existing guidance on accounting for leases in Leases (Topic

840

) and generally requires all leases to be recognized in the consolidated balance sheet. ASU

2016

is effective for annual and interim reporting periods beginning after

December 15, 2018;

early adoption is permitted. We do

not

plan to elect early adoption. The provisions of ASU

2016

are to be applied using a modified retrospective approach, or if we elect we

may

use a cumulative-effect adjustment to retained earnings as of

January

2019.

We are currently assessing the future impact of this ASU on our consolidated financial statements.

June 2018,

the FASB issued ASU

2018

Compensation – Stock Compensation (Topic

718

): Improvements to Nonemployee Share-Based Payment Accounting, (ASU

2018

). ASU

2018

expands the scope of Topic

718

2018

is effective for fiscal years beginning after

December

15,

2018

and is to be adopted through a cumulative-effect adjustment to retained earnings as of

January

2019

for then outstanding share-based payments to nonemployees. We are currently assessing the future impact of this ASU on our consolidated financial statements.

Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, and the American Institute of Certified Public Accountants did

not

or are

not

believed by management to have a material impact on the Company’s financial statement presentation or disclosures.

XML 28 R17.htm IDEA: XBRL DOCUMENT

Note 3 - Fair Value Measurement (Tables)

6 Months Ended

Jun. 30, 2018

Notes Tables

Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]

	As of June 30, 2018

	Level 1		Level 2		Level 3		Total
Assets:
Cash equivalents	$	6,383	$	—	$	—	$	6,383

	As of December 31, 2017
	Level 1		Level 2		Level 3		Total
Assets:
Cash equivalents	$	12,063	$	—	$	—	$	12,063

XML 29 R18.htm IDEA: XBRL DOCUMENT

Note 4 - Inventories (Tables)

6 Months Ended

Jun. 30, 2018

Notes Tables

Schedule of Inventory, Current [Table Text Block]

	June 30, 2018		December 31, 2017
Raw materials	$	63	$	70
Work in process		29		92
Finished goods		44		29
Total	$	136	$	191

XML 30 R19.htm IDEA: XBRL DOCUMENT

Note 5 - Property and Equipment, Net (Tables)

6 Months Ended

Jun. 30, 2018

Notes Tables

Property, Plant and Equipment [Table Text Block]

	June 30, 2018			December 31, 2017
Computer equipment and software	$	114		$	106
Laboratory and manufacturing equipment		471			447
Furniture and fixtures		55			48
Leasehold improvements		326			326
Property and equipment, gross		966			927
Less accumulated depreciation		(802	)		(758	)
Property and equipment, net	$	164		$	169

XML 31 R20.htm IDEA: XBRL DOCUMENT

Note 6 - Accrued Expenses and Other Current Liabilities (Tables)

6 Months Ended

Jun. 30, 2018

Notes Tables

Schedule of Accrued Liabilities and Other Current Liabilities [Table Text Block]

	June 30, 2018		December 31, 2017
Accrued expenses	$	180	$	129
Accrued employee costs		412		410
Grant liability		635		663
Customer deposits		87		61
Total	$	1,314	$	1,263

XML 32 R21.htm IDEA: XBRL DOCUMENT

Note 7 - Share-based Compensation (Tables)

6 Months Ended

Jun. 30, 2018

Notes Tables

Schedule of Share-based Compensation, Expense [Table Text Block]

	Three months ended June 30,				Six months ended June 30,
	2018		2017		2018		2017
Cost of goods sold	$	36	$	33	$	66	$	74
Research and development		264		154		461		326
Selling, general and administrative		438		489		826		898
Share-based compensation expense	$	738	$	676	$	1,353	$	1,298

Share-based Compensation, Stock Options, Activity [Table Text Block]

				Weighted
				average
	Number of			exercise
	shares			price
Balance, December 31, 2017		4,213,100		$	2.96
Stock options granted		1,603,075			2.48
Stock options exercised		(2,488	)		1.80
Stock options cancelled		(135,487	)		2.69
Balance, June 30, 2018		5,678,200		$	2.83

Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]

				Weighted
				average
				grant date
	Number of			fair value
	shares			per share
Balance, December 31, 2017		97,996		$	8.71
RSUs vested		(57,108	)		7.03
Balance, June 30, 2018		40,888		$	11.04

Non-employee Stock Options [Member]

Notes Tables

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]

Risk-free interest rate	2.80%	-	2.84%
Volatility	78%	-	80%
Dividend yield		None
Expected term (in years)	8.1	-	8.8

Employee Stock Option [Member]

Notes Tables

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]

Risk-free interest rate	2.66%	-	2.87%
Volatility		81%
Dividend yield		None
Expected term (in years)		6.25

XML 33 R22.htm IDEA: XBRL DOCUMENT

Note 8 - Net Loss Per Share (Tables)

6 Months Ended

Jun. 30, 2018

Notes Tables

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]

	June 30,
	2018		2017
Stock options to purchase common stock		5,678,200		4,008,634
Unvested restricted stock units		40,888		98,000
Total		5,719,088		4,106,634

XML 34 R23.htm IDEA: XBRL DOCUMENT

Note 2 - Significant Accounting Policies (Details Textual) - USD ($)	Jun. 30, 2018	Jan. 01, 2018	Dec. 31, 2017	Jun. 30, 2017	Dec. 31, 2016
Retained Earnings (Accumulated Deficit), Ending Balance	$ (79,175,000)		$ (72,450,000)
Cash and Cash Equivalents, at Carrying Value, Ending Balance	$ 6,834,000		$ 12,689,000	$ 15,109,000	$ 21,352,000
Accounting Standards Update 2014-09 [Member]
Retained Earnings (Accumulated Deficit), Ending Balance		$ (76,000)

XML 35 R24.htm IDEA: XBRL DOCUMENT

Note 3 - Fair Value Measurement - Fair Value of Assets Measured on a Recurring Basis (Details) - Fair Value, Measurements, Recurring [Member] - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Assets:
Cash equivalents	$ 6,383	$ 12,063
Fair Value, Inputs, Level 1 [Member]
Assets:
Cash equivalents	6,383	12,063
Fair Value, Inputs, Level 2 [Member]
Assets:
Cash equivalents
Fair Value, Inputs, Level 3 [Member]
Assets:
Cash equivalents

XML 36 R25.htm IDEA: XBRL DOCUMENT

Note 4 - Inventories (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
Note 4 - Inventories (Details Textual) - USD ($)	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Inventory Write-down	$ 12,000	$ 1,000	$ 15,000	$ 10,000

XML 37 R26.htm IDEA: XBRL DOCUMENT

Note 4 - Inventories - Summary of Inventories (Details) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Raw materials	$ 63	$ 70
Work in process	29	92
Finished goods	44	29
Total	$ 136	$ 191

XML 38 R27.htm IDEA: XBRL DOCUMENT

Note 5 - Property and Equipment, Net - Summary of Property and Equipment, Net (Details) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Property and equipment, gross	$ 966	$ 927
Less accumulated depreciation	(802)	(758)
Property and equipment, net	164	169
Computer Equipment and Software [Member]
Property and equipment, gross	114	106
Laboratory and Manufacturing Equipment [Member]
Property and equipment, gross	471	447
Furniture and Fixtures [Member]
Property and equipment, gross	55	48
Leasehold Improvements [Member]
Property and equipment, gross	$ 326	$ 326

XML 39 R28.htm IDEA: XBRL DOCUMENT

Note 6 - Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Accrued expenses	$ 180	$ 129
Accrued employee costs	412	410
Grant liability	635	663
Customer deposits	87	61
Total	$ 1,314	$ 1,263

XML 40 R29.htm IDEA: XBRL DOCUMENT

Note 7 - Share-based Compensation (Details Textual) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Employee Service Share-based Compensation, Allocation of Recognized Period Costs, Capitalized Amount	$ 0	$ 0	$ 0	$ 0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value			$ 1.77
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross			1,603,075
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options	6,300,000		$ 6,300,000
Allocated Share-based Compensation Expense, Total	738,000	676,000	$ 1,353,000	1,298,000
Consultants [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross			0
Non-employees [Member]
Allocated Share-based Compensation Expense, Total	31,000	$ 277,000	$ 76,000	$ 510,000
Employee Stock Option [Member]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition			2 years 292 days
Restricted Stock Units (RSUs) [Member]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition			1 year 182 days
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options	$ 348,000		$ 348,000

XML 41 R30.htm IDEA: XBRL DOCUMENT

Note 7 - Share-based Compensation - Share-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Share-based compensation expense	$ 738	$ 676	$ 1,353	$ 1,298
Cost of Goods Sold [Member]
Share-based compensation expense	36	33	66	74
Research and Development Expense [Member]
Share-based compensation expense	264	154	461	326
Selling, General and Administrative Expenses [Member]
Share-based compensation expense	$ 438	$ 489	$ 826	$ 898

XML 42 R31.htm IDEA: XBRL DOCUMENT

Note 7 - Share-based Compensation - Stock Option Activity (Details)	6 Months Ended
	Jun. 30, 2018 $ / shares shares
Stock options outstanding, beginning of period (in shares) \| shares	4,213,100
Balance, weighted average exercise price, beginning of period (in dollars per share) \| $ / shares	$ 2.96
Stock options granted (in shares) \| shares	1,603,075
Stock options granted, weighted average exercise price (in dollars per share) \| $ / shares	$ 2.48
Stock options exercised (in shares) \| shares	(2,488)
Stock options exercised, weighted average exercise price (in dollars per share) \| $ / shares	$ 1.80
Stock options cancelled (in shares) \| shares	(135,487)
Stock options cancelled, weighted average exercise price (in dollars per share) \| $ / shares	$ 2.69
Stock options outstanding, end of period (in shares) \| shares	5,678,200
Balance, weighted average exercise price, end of period (in dollars per share) \| $ / shares	$ 2.83

XML 43 R32.htm IDEA: XBRL DOCUMENT

Note 7 - Share-based Compensation - Valuation Assumptions for Employee Stock Options (Details) - Employee Stock Option [Member]	6 Months Ended
	Jun. 30, 2018
Volatility	81.00%
Dividend yield	0.00%
Expected term (in years) (Year)	6 years 91 days
Minimum [Member]
Risk-free interest rate	2.66%
Maximum [Member]
Risk-free interest rate	2.87%

XML 44 R33.htm IDEA: XBRL DOCUMENT

Note 7 - Share-based Compensation - Summary of Non-vested RSUs (Details) - Restricted Stock Units (RSUs) [Member]	6 Months Ended
	Jun. 30, 2018 $ / shares shares
Balance, Shares (in shares) \| shares	97,996
Balance, Weighted average grant date fair value per share (in dollars per share) \| $ / shares	$ 8.71
RSUs vested, Shares (in shares) \| shares	(57,108)
RSUs vested, Weighted average grant date fair value per share (in dollars per share) \| $ / shares	$ 7.03
Balance, Shares (in shares) \| shares	40,888
Balance, Weighted average grant date fair value per share (in dollars per share) \| $ / shares	$ 11.04

XML 45 R34.htm IDEA: XBRL DOCUMENT

Note 7 - Share-based Compensation - Nonemployee Stock Option Valuation Assumptions (Details) - Non-employee Stock Options [Member]	6 Months Ended
	Jun. 30, 2018
Dividend yield	0.00%
Minimum [Member]
Risk-free interest rate	2.80%
Volatility	78.00%
Expected term (in years) (Year)	8 years 36 days
Maximum [Member]
Risk-free interest rate	2.84%
Volatility	80.00%
Expected term (in years) (Year)	8 years 292 days

XML 46 R35.htm IDEA: XBRL DOCUMENT

Note 8 - Net Loss Per Share - Anti-dilutive Securities (Details) - shares	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Antidilutive securities (in shares)	5,719,088	4,106,634
Employee Stock Option [Member]
Antidilutive securities (in shares)	5,678,200	4,008,634
Restricted Stock Units (RSUs) [Member]
Antidilutive securities (in shares)	40,888	98,000

XML 47 R36.htm IDEA: XBRL DOCUMENT

Note 9 - Income Taxes (Details Textual) - USD ($) $ in Thousands	6 Months Ended		12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2018	Dec. 31, 2017
Income Tax Expense (Benefit), Total	$ 0	$ 0
Deferred Tax Liabilities, Net, Total	$ 0
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent				35.00%
Scenario, Forecast [Member]
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent			21.00%

XML 48 R37.htm IDEA: XBRL DOCUMENT

Note 10 - Related Party Transactions (Details Textual) - USD ($)	1 Months Ended	3 Months Ended		6 Months Ended
	Aug. 31, 2016	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross				1,603,075
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance		$ 2.83		$ 2.83		$ 2.96
Allocated Share-based Compensation Expense, Total		$ 738,000	$ 676,000	$ 1,353,000	$ 1,298,000
OPKO [Member]
Related Party, Ownership Percentage	5.00%
OPKO [Member] \| Consulting Services [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	418,977
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	4 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance	$ 1.80
Allocated Share-based Compensation Expense, Total				62,000	$ 306,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Grant Date Fair Value		$ 5,300,000		$ 5,300,000
Consulting Agreement, Term	4 years
Consulting Agreement, Term, Length of Automatic Renewal Periods	1 year
Chairman and Chief Executive Officer of OPKO [Member]
Related Party, Ownership Percentage	5.00%

EXCEL 49 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end

XML 50 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 51 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 53 FilingSummary.xml IDEA: XBRL DOCUMENT 3.10.0.1 html 73 138 1 false 27 0 false 4 false false R1.htm 000 - Document - Document And Entity Information Sheet http://www.biocardia.com/20180630/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false R2.htm 001 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) Sheet http://www.biocardia.com/20180630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited Condensed Consolidated Balance Sheets (Current Period Unaudited) Statements 2 false false R3.htm 002 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) Sheet http://www.biocardia.com/20180630/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) Statements 3 false false R4.htm 003 - Statement - Condensed Consolidated Statements of Operations (Unaudited) Sheet http://www.biocardia.com/20180630/role/statement-condensed-consolidated-statements-of-operations-unaudited Condensed Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 004 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://www.biocardia.com/20180630/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 5 false false R6.htm 005 - Disclosure - Note 1 - Summary of Business and Basis of Presentation Sheet http://www.biocardia.com/20180630/role/statement-note-1-summary-of-business-and-basis-of-presentation Note 1 - Summary of Business and Basis of Presentation Notes 6 false false R7.htm 006 - Disclosure - Note 2 - Significant Accounting Policies Sheet http://www.biocardia.com/20180630/role/statement-note-2-significant-accounting-policies Note 2 - Significant Accounting Policies Notes 7 false false R8.htm 007 - Disclosure - Note 3 - Fair Value Measurement Sheet http://www.biocardia.com/20180630/role/statement-note-3-fair-value-measurement Note 3 - Fair Value Measurement Notes 8 false false R9.htm 008 - Disclosure - Note 4 - Inventories Sheet http://www.biocardia.com/20180630/role/statement-note-4-inventories Note 4 - Inventories Notes 9 false false R10.htm 009 - Disclosure - Note 5 - Property and Equipment, Net Sheet http://www.biocardia.com/20180630/role/statement-note-5-property-and-equipment-net Note 5 - Property and Equipment, Net Notes 10 false false R11.htm 010 - Disclosure - Note 6 - Accrued Expenses and Other Current Liabilities Sheet http://www.biocardia.com/20180630/role/statement-note-6-accrued-expenses-and-other-current-liabilities Note 6 - Accrued Expenses and Other Current Liabilities Notes 11 false false R12.htm 011 - Disclosure - Note 7 - Share-based Compensation Sheet http://www.biocardia.com/20180630/role/statement-note-7-sharebased-compensation Note 7 - Share-based Compensation Notes 12 false false R13.htm 012 - Document - Note 8 - Net Loss Per Share Sheet http://www.biocardia.com/20180630/role/statement-note-8-net-loss-per-share Note 8 - Net Loss Per Share Uncategorized 13 false false R14.htm 013 - Disclosure - Note 9 - Income Taxes Sheet http://www.biocardia.com/20180630/role/statement-note-9-income-taxes- Note 9 - Income Taxes Uncategorized 14 false false R15.htm 014 - Disclosure - Note 10 - Related Party Transactions Sheet http://www.biocardia.com/20180630/role/statement-note-10-related-party-transactions Note 10 - Related Party Transactions Uncategorized 15 false false R16.htm 015 - Disclosure - Significant Accounting Policies (Policies) Sheet http://www.biocardia.com/20180630/role/statement-significant-accounting-policies-policies Significant Accounting Policies (Policies) Uncategorized 16 false false R17.htm 016 - Disclosure - Note 3 - Fair Value Measurement (Tables) Sheet http://www.biocardia.com/20180630/role/statement-note-3-fair-value-measurement-tables Note 3 - Fair Value Measurement (Tables) Uncategorized 17 false false R18.htm 017 - Disclosure - Note 4 - Inventories (Tables) Sheet http://www.biocardia.com/20180630/role/statement-note-4-inventories-tables Note 4 - Inventories (Tables) Uncategorized 18 false false R19.htm 018 - Disclosure - Note 5 - Property and Equipment, Net (Tables) Sheet http://www.biocardia.com/20180630/role/statement-note-5-property-and-equipment-net-tables Note 5 - Property and Equipment, Net (Tables) Uncategorized 19 false false R20.htm 019 - Disclosure - Note 6 - Accrued Expenses and Other Current Liabilities (Tables) Sheet http://www.biocardia.com/20180630/role/statement-note-6-accrued-expenses-and-other-current-liabilities-tables Note 6 - Accrued Expenses and Other Current Liabilities (Tables) Uncategorized 20 false false R21.htm 020 - Disclosure - Note 7 - Share-based Compensation (Tables) Sheet http://www.biocardia.com/20180630/role/statement-note-7-sharebased-compensation-tables Note 7 - Share-based Compensation (Tables) Uncategorized 21 false false R22.htm 021 - Disclosure - Note 8 - Net Loss Per Share (Tables) Sheet http://www.biocardia.com/20180630/role/statement-note-8-net-loss-per-share-tables Note 8 - Net Loss Per Share (Tables) Uncategorized 22 false false R23.htm 022 - Disclosure - Note 2 - Significant Accounting Policies (Details Textual) Sheet http://www.biocardia.com/20180630/role/statement-note-2-significant-accounting-policies-details-textual Note 2 - Significant Accounting Policies (Details Textual) Uncategorized 23 false false R24.htm 023 - Disclosure - Note 3 - Fair Value Measurement - Fair Value of Assets Measured on a Recurring Basis (Details) Sheet http://www.biocardia.com/20180630/role/statement-note-3-fair-value-measurement-fair-value-of-assets-measured-on-a-recurring-basis-details Note 3 - Fair Value Measurement - Fair Value of Assets Measured on a Recurring Basis (Details) Uncategorized 24 false false R25.htm 024 - Disclosure - Note 4 - Inventories (Details Textual) Sheet http://www.biocardia.com/20180630/role/statement-note-4-inventories-details-textual Note 4 - Inventories (Details Textual) Uncategorized 25 false false R26.htm 025 - Disclosure - Note 4 - Inventories - Summary of Inventories (Details) Sheet http://www.biocardia.com/20180630/role/statement-note-4-inventories-summary-of-inventories-details Note 4 - Inventories - Summary of Inventories (Details) Uncategorized 26 false false R27.htm 026 - Disclosure - Note 5 - Property and Equipment, Net - Summary of Property and Equipment, Net (Details) Sheet http://www.biocardia.com/20180630/role/statement-note-5-property-and-equipment-net-summary-of-property-and-equipment-net-details Note 5 - Property and Equipment, Net - Summary of Property and Equipment, Net (Details) Uncategorized 27 false false R28.htm 027 - Disclosure - Note 6 - Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Details) Sheet http://www.biocardia.com/20180630/role/statement-note-6-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-and-other-current-liabilities-details Note 6 - Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Details) Uncategorized 28 false false R29.htm 028 - Disclosure - Note 7 - Share-based Compensation (Details Textual) Sheet http://www.biocardia.com/20180630/role/statement-note-7-sharebased-compensation-details-textual Note 7 - Share-based Compensation (Details Textual) Uncategorized 29 false false R30.htm 029 - Disclosure - Note 7 - Share-based Compensation - Share-based Compensation Expense (Details) Sheet http://www.biocardia.com/20180630/role/statement-note-7-sharebased-compensation-sharebased-compensation-expense-details Note 7 - Share-based Compensation - Share-based Compensation Expense (Details) Uncategorized 30 false false R31.htm 030 - Disclosure - Note 7 - Share-based Compensation - Stock Option Activity (Details) Sheet http://www.biocardia.com/20180630/role/statement-note-7-sharebased-compensation-stock-option-activity-details Note 7 - Share-based Compensation - Stock Option Activity (Details) Uncategorized 31 false false R32.htm 031 - Disclosure - Note 7 - Share-based Compensation - Valuation Assumptions for Employee Stock Options (Details) Sheet http://www.biocardia.com/20180630/role/statement-note-7-sharebased-compensation-valuation-assumptions-for-employee-stock-options-details Note 7 - Share-based Compensation - Valuation Assumptions for Employee Stock Options (Details) Uncategorized 32 false false R33.htm 032 - Disclosure - Note 7 - Share-based Compensation - Summary of Non-vested RSUs (Details) Sheet http://www.biocardia.com/20180630/role/statement-note-7-sharebased-compensation-summary-of-nonvested-rsus-details Note 7 - Share-based Compensation - Summary of Non-vested RSUs (Details) Uncategorized 33 false false R34.htm 033 - Disclosure - Note 7 - Share-based Compensation - Nonemployee Stock Option Valuation Assumptions (Details) Sheet http://www.biocardia.com/20180630/role/statement-note-7-sharebased-compensation-nonemployee-stock-option-valuation-assumptions-details Note 7 - Share-based Compensation - Nonemployee Stock Option Valuation Assumptions (Details) Uncategorized 34 false false R35.htm 034 - Disclosure - Note 8 - Net Loss Per Share - Anti-dilutive Securities (Details) Sheet http://www.biocardia.com/20180630/role/statement-note-8-net-loss-per-share-antidilutive-securities-details Note 8 - Net Loss Per Share - Anti-dilutive Securities (Details) Uncategorized 35 false false R36.htm 035 - Disclosure - Note 9 - Income Taxes (Details Textual) Sheet http://www.biocardia.com/20180630/role/statement-note-9-income-taxes-details-textual Note 9 - Income Taxes (Details Textual) Uncategorized 36 false false R37.htm 036 - Disclosure - Note 10 - Related Party Transactions (Details Textual) Sheet http://www.biocardia.com/20180630/role/statement-note-10-related-party-transactions-details-textual Note 10 - Related Party Transactions (Details Textual) Uncategorized 37 false false All Reports Book All Reports bcda-20180630.xml bcda-20180630.xsd bcda-20180630_cal.xml bcda-20180630_def.xml bcda-20180630_lab.xml bcda-20180630_pre.xml http://fasb.org/us-gaap/2018-01-31 http://fasb.org/srt/2018-01-31 http://xbrl.sec.gov/dei/2018-01-31 true true ZIP 55 0001437749-18-015094-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001437749-18-015094-xbrl.zip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end